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Higher eukaryotes produce a vast range of antimicrobial peptides (AMPs) that play 
important roles in their defence against microbial infection. Beta defensins are small 
(3-5 kDa), cationic peptides that display broad, potent antimicrobial activity against a 
range of microbes and also act as chemoattractants of important immunomodulatory 
cells. To generate highly pure peptides for structural and functional studies, we 
developed a method to prepare recombinant human beta defensin-2 (HBD2). The 
HBD2 gene was synthesised by recursive PCR with codons optimised for expression 
in Escherichia coli. HBD2 was expressed as an insoluble fusion to a His-tagged 
ketosteroid isomerase. After cleavage from the fusion with cyanogen bromide, 1H 
NMR spectroscopy and mass spectrometry confirmed that the oxidised HBD2 was 
folded and possessed the correct β-defensin disulfide bond topology. The recombinant 
HBD2 was active against E. coli, P. aeruginosa, S. aureus and C. albicans and was 
also a chemoattractant against HEK293 cells expressing the chemokine receptor 
CCR6. 15N-labelled HBD2 was also prepared and was highly suitable for future 
structural studies. Since defensins are thought to interact with bacterial membranes we 
also tested the recombinant HBD2 in biophysical studies (surface plasmon resonance, 
SPR, Biacore). We observed different binding to artificial model membranes 
containing either E. coli Kdo2-lipid A or phospholipids. 
 Bacterial resistance to AMPs has been linked to the covalent modification of 
the outer membrane lipid A by 4-amino-4-deoxy-L-arabinose (L-Ara4N). This 
neutralises the charge of the LPS, thereby decreasing the electrostatic attraction of 
cationic peptides to the bacterial membrane. The pathogen Burkholderia cenocepacia 
displays extremely high resistance to AMPs and other antibiotics and the Ara4N 
pathway appears to be essential. To explore this further we expressed recombinant 
forms of two enzymes (ArnB and ArnG) from the B. cenocepacia Ara4N pathway. 
Purified ArnB is a pyridoxal 5’-phosphate (PLP)-dependent transaminase and we 
tested its ability to bind amino acid substrates. We investigated the binding of 
inhibitors L- and D-cycloserine to ArnB and tested their antibiotic activity against 
Burkholderia strains. We also studied the B. cenocepacia ArnG – a proposed 
membrane protein undecaprenyl-L-Ara4N flippase – and showed that the protein 
behaved as a dimer by non-denaturing gel analysis. The B. cenocepacia ArnG failed 
to complement E. coli knock-out strains encoding the equivalent flippase proteins 





Aa Amino acid(s) 
AMP Antimicrobial peptide 
APS Ammonium persulfate 
ArnT L-Ara4N transferase 
Bcc Burkholderia cepacia complex 
CF Cystic fibrosis 
CFTR Cystic fibrosis transmembrane conductance regulator 
cfu Colony forming units 
Da Dalton 
DDM n-Dodecyl-β-maltoside  
DDT Dithiothreitol 
EDTA Ethylenediaminetetracetic acid 
ESI-MS Electrospray ionisation mass spectroscopy 
FPLC Fast protein liquid chromatography 
FT-ICR Fourier transform ion cyclotron resonance 
HBD1 Human β-defensin-1 
HBD2 Human β-defensin-2 
HBD3 Human β-defensin-3 
HBD4 Human β-defensin-4 
g Gravity (centrifugal force) 
HEPES N-(2-Hydroxyethyl)piperazine-N`-(2-ethanesulfonic acid) 
IMAC Immobilized metal affinity chromatography 
IPTG Isopropyl-1-thio-β−D-galactopyranoside 




ISB Isosensitest broth 
kDa Kilo daltons 
Kdo 3-deoxy-D-manno-oct-2-ulosonic acid 
Ko D-glycero-α-D-talo-oct-2-ulosonic acid 
L-Ara4N  4-amino-4-deoxy-β-L-arabinose 
LB Luria Bertani 
LC-MS Liquid chromatography mass spectrometry 
LD Lethal dose  
LPS Lipopolysaccharide 
MIC Minimum inhibitory concentration 
PAGE Polyacrylamide gel electrophoresis 
PLP Pyridoxal 5’-phosphate 
PMP Pyridoxamine phosphate 
PBS Phosphate buffered solution 
PCR Polymerase chain reaction 
PET Phospoethanolamine 
PMB Polymyxin B 
SDS Sodium dodecylsulfate 
SPR Surface plasmon resonance 
SPPS Solid Phase Peptide Synthesis 
TB Terrific broth 
TCEP Tris carboxyethylphosphine 
TFA Trifluoroacetic acid 
Tris Tris [hydroxymethyl] aminomethane 
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Ugd UDP-glucose dehydrogenase 
UV-Vis Ultraviolet- visible spectroscopy 
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“There is probably no chemotherapeutic drug to which in suitable circumstances the 
bacteria cannot react by in some way acquiring ‘fastness’ [resistance]” 
- Alexander Fleming, 1946
Chapter 1: Defensins 
2 
1.1 The Expanding Diversity of The Antimicrobial Peptide Family 
 
Defensins belong to a large family of small molecules called antimicrobial peptides 
(AMPs). To date more than 900 examples of such AMPs have been reported and 
classified [1]. This classification is divided into different categories based on their 
structures and topologies. They are spread throughout all kingdoms and phylum and 
display a well-recognized broad-spectrum antimicrobial activity at physiological 
concentrations. Growing interest within this field has also allowed the observations of 
their potent action towards fungi and viruses. AMPs are therefore considered as 
important components of the innate immune system and are also effective modulators 
of the adaptive immune system. An online database for antimicrobial peptides is 
available at http://aps.unmc.edu/AP/main.php [2]. The majority of peptides found in 
this database (97%) are less than 50 amino acids long and have an average length of 
28 residues. Other common traits associated with this family (96%) are the net 
positive charge shared by such peptides (also known as cationic antimicrobial 
peptides, cAMPS) and also their ability to adopt an organised fold with hydrophobic 
patches [3]. These two characteristics define of their amphipathic nature. 
Interestingly, small anionic pro-peptides have been described and their antimicrobial 
activities have been tested against both Gram-negative and Gram-positive bacteria. 
However such peptides remain marginal in comparison with their cationic 
homologues and are restricted to a few animal species [4]. Different groups of 
peptides within the cAMPs family have emerged in the last few decades; these 
include the epidermal cathelicidins [5] and defensins [6] which are human peptides. 
Other classes of AMPs have been isolated, characterised and classified mainly under 
their structural differences. Examples of their diversity are given in Table 1.1.  
 The growing interest in AMPs over the years has encouraged researchers to 
investigate their potential use as new therapeutics [7, 8, 9]. For example their 
structural and functional diversity has made such peptides ideal candidates for novel 
antibiotics. It is thought that resistance towards AMPs requires more than a simple 
genetic “trick” to counterfeit their action as a drastic modification of the lipid 
membrane composition and topology is required [10, 11]. 
 

Chapter 1: Defensins 
3 





Cathelicidin (LL37) (human) 
Cecropin, melittin, andropin, 
ceratotoxin (insect) 
Maiganin 2 (frog) 
Buforin II  (amphibian) 
CAP18 (rabbit)
 
No cysteine, adopt an 
amphipathic α-helical 





Histatin 5 (human) 
PR39 (pig) 
Indolicidin (cow) 
Apidaecins, abaecin, (honeybee) 

Proline, arginine, histidine 
or tryptophane-rich 
peptides 
One or two 
disulfide bonds 













antiparallel βsheets motif 
(except forθ-Def.)

Table 1.1. Examples of AMPs diversity. A non-exhaustive list of AMPs organised 
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1.2 Defensins  
 
1.2.1 Structural Classification  
 
Defensins are a subset of the larger and expanding AMPs family and are characterised 
by a triple β-sheet fold held together by six conserved cysteine residues that oxidise to 
form three disulfide (S-S) bonds. Two main subgroups of defensins have been defined 
according to the topology of these three S-S bonds. Hence the alpha (α-) defensins 
display a S-S connectivity of Cys1-Cys6, Cys2-Cys4 and Cys3-Cys5 whereas beta (β-) 
defensins share a Cys1-Cys5, Cys2-Cys4, Cys3-Cys6 S-S connectivity (Fig. 1.1). The α-
defensins contain ~29-35 residues while β-defensins present a longer primary 
sequence that comprises ~40-50 residues. An additional class of defensins have been 
described, the θ-defensins. θ-Defensins are the most recently identified subfamily of 
defensins. Rhesus theta-defensins (RTDs), also known as retrocyclins, were isolated 











Figure 1.1 The disulfide bridging connectivity in α, β, and θ-defensins. The S-S bond 
connectivites are indicated with the blue connectors.  
 




This peptide was isolated from the rhesus monkey polymorphonuclear leucocytes 
(PMNs) [13]. θ-Defensins are cyclic peptides fused at their N- and C- termini but also 
display three disulfide bridges. The three different disulfide bridge topologies found 
in the three defensin classes are described in figure 1.1. 
 
1.2.2 From the Innate to the Adaptive immune system 
 
Despite the fact that the antimicrobial function of defensins (discussed later) has been 
extensively studied and still remains the main focus for a large number of research 
groups, additional properties have been described and attributed to such molecules. 
Mammals share their environment with numerous potentially pathogenic 
microorganisms. Natural barriers such as mucous membranes and skin protect them 
from microbial disease. However, when the epithelial “shield” is weakened or 
breached, invading pathogens are eliminated by the innate immune system, the first 
protective mechanism employed [14]. This first reaction is followed by a second 
protective phenomenon called the adaptive immune response.  
 In the mammalian innate immune response, a rapid mobilised host defence is 
activated at a basal level in a time quick enough to avoid any microbial replication 
and therefore an imminent invasion. It includes different cells effectors such as 
epithelial cells, mast cells, neutrophils, macrophage cells or natural killer cells [15]. 
Components from invading pathogens (known as Pathogen-associated molecular 
patterns, PAMPs) activate cell-surface receptors such as Toll-like receptors (TLRs), 
which results in the release of various mediators such as the complement cascade, 
cytokines, chemokines and antimicrobial peptides including defensins and 
cathelicidin. Cathelicidin (LL37/hCAP-18), stored by specific (secondary) granules, is 
encoded by one gene [16] and expressed on all epithelial areas [17]. When these 
mediators are released, they recruit and activate PMNs. In humans, α-defensins, also 
known as human neutrophil peptides (HNP1 to HNP4) are localised in high 
concentrations in azurophilic granules (primary) and paneth cell granules [18, 19]. 
Neutrophils in contact with the ingested microorganism release α-defensins into the 
surroundings such that they reach a high localised concentration of peptides (over 10 
Chapter 1: Defensins 
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mg/ml). Other peptides related to the α-defensin family, human defensin 5 and 6 
(HD5 and HD6) are constitutively expressed in the Paneth cells located in the small 
intestine. From the intestinal crypt HD5 and HD6 are excreted to the lumen [20, 21]. 
In 2003, Salzman and coworkers demonstrated that transgenic mice expressing HD5 
appear to be more resistant against virulent, orally-injected Salmonella typhimurium 
bacteria than non-transgenic candidates [22].  
 The second major group of defensins, the β-defensins, are also involved in the 
host defense system. In humans, only four β-defensins (HBD1 to HBD4) have been 
described and studied in detail to date, however more than 30 loci have been 
identified in the human genome [23]. HBD1 is constitutively expressed in various 
tissues [24, 25] in the epithelial cells of the respiratory and urinary tracts [26, 27]. 
Bals and coworkers have demonstrated that the lack of the mouse β-defensin-1 gene 
(mBD1), the murine homologue of HBD1, resulted in delayed clearance of 
Haemophilus influenzae from the lungs in a knock-out mouse model [28] and an 
associated increased load of Staphylococcus in the bladder [29]. In contrast to the 
constitutively expressed HBD1, defensins HBD2, 3 and 4 are inducible peptides 
produced by epithelial and keratinocytes cells in response to proinflammatory stimuli. 
This production can be stimulated by various elements such as lipopolysaccharides 
(LPS), interleukins (IL), tumour necrosis factor (TNF) or histamines [30, 31].  
 There is no doubt that defensins play a key role in the innate immune system 
but recent studies have also pointed out their involvement in the adaptive immune 
response [32]. This response differs from the innate defense response as it is a delayed 
physiological mechanism that occurs for weeks after a host invasion. If the innate 
immune reaction is clinically “silent”, the adaptive response always triggers an 
inflammatory process. However, despite the fact that these two systems have usually 
been opposed or complemented, recent studies have shown that the immune system 
could be described as a continuum organisation rather than the dichotomic paradigm 
by which it is usually referred [33]. Antimicrobial peptides such as defensins could 
play an important role in this continuum organisation as growing evidence highlights 
their ability to link the innate to the adaptive immune system.  
Various studies have shed light on the interaction of defensins with receptors 
located on lymphocytes and immature dendritic cells (DCs) that lead to the activation 
of an adaptive response. Almost 20 years ago Territo and coworkers showed that 
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HNP1 and HNP2 were chemotactic for human monocytes in vitro [34]. The migration 
of some human T lymphocytes including naïve CD4 and CD8 T cells by human α-
defensins was observed. Such peptides were also able to recruit human dendritic cells 
[35]. Human β-defensins 1, 2 and 3 were reported to be chemotactic for CD4 memory 
T cells, immature (but not mature) DCs but also for human TNF-α-treated neutrophils 
[36, 37, 38]. The β-defensins in these studies appear to bind and activate a G-protein-
coupled receptor (GPCR), the chemokine-coupled receptor 6 (CCR6). This receptor 
was previously shown to bind the chemokine MIP-3α (also known as CCL20), but β-
defensins display similar structured motifs and charge distribution with this “natural” 
CCR6 ligand despite very low homology sequences [39]. Interestingly, MIP-3α has 
also been shown to be microbicidal [40]. The resemblance between the two molecules 
has led β-defensins to be considered as chemokine-like peptides.  
 
1.2.3 Antiviral Properties  
 
In addition to their biological action in both innate and adaptive systems, defensins 
have been reported to display antiviral activities. In the mid 1980’s, human NP1, NP2 
and NP3 were tested against a range of viruses including herpes simplex types 1 and 2 
viruses (HSV-1 and HSV-2), influenza A virus, cytomegalovirus and vesicular 
stomatitis virus. Studies showed that these viruses when preincubated with such 
peptides have the capacity to lose their property to infect target cells [41]. Similar 
conclusions were reached with rabbit NP1 and NP2 with the exception of 
cytomegalovirus and two non-enveloped viruses which retained their infectivity [42]. 
More recently, the inactivation mechanism of NP1 towards HSV-2 was analysed in 
detail. This study revealed that despite the fact that NP1 did not prevent glycoproteins 
from the viral envelope binding to the heparan sulfate receptors located on the host 
cell, it did prohibit cell-to-cell spreading and viral entry [43]. Moreover, the ability of 
many defensins to bind glycans specifically has led to the idea that defensins are 
lectins [44, 45]. The recent study of the human α-defensin 5 (HD5) bound to natural 
glycoproteins in a self-association and multivalent manner has enhanced the belief 
that such lectin-like peptides protect humans from viral infection and other invading 
agents [46]. This antiviral activity appears to be a common trait among the three 
defensin families. Thus, the rhesus θ-defensins (RTD1-3), α-defensins [47, 48, 49] 
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and β-defensins (HBD2-3), have also been reported to protect cells from an invasion 
by viruses such as the human immunodeficiency virus 1 (HIV-1), HSV-1 and HSV-2 
viruses. In the θ-defensins family, RTD-2 was the most efficient peptide against HIV-
1 and HSV-2 viruses [50]. Concerning the β-defensin family, Quinones-Mateu and 
coworkers demonstrated that HBD2 and HBD3 peptides could not only inhibit HIV-1 
replication, but were also induced by this virus [51]. In contrast, HBD1 expression is 
highly reduced in alveolar macrophages in patients infected with HIV but not in nasal 
epithelial cells [52].  
 
1.2.4 Additional Biological Functions  
 
Recent reports have provided new insight into the physiological functions of 
defensins, in particular the β-subgroup. Seminal studies have identified some 
relationships between stages of development or types of tumors and the expression 
patterns of β-defensins [53, 54]. HBD1 was revealed to be a good 
immunohistochemical marker for the diagnosis of prostate and renal tumors [55].  
 A remarkable upregulation of HBD1 and HBD3 mRNA was observed in the 
maturation of keratinocytes indicating a plausible involvement of such peptides in the 
cell differentiation mechanisms [56]. Moreover, the expression of HBD3 was also 
observed in osteoarthritic (OA) joints leading Varoga and coworkers to suggest a role 
for HBD3 in tissue-remodeling processes [57].  
 Although defensins were originally considered and categorised as merely 
antimicrobial peptides, which still remains an area of interest for many research 
programs, it is now clear that this ability constitutes only the “tip of the iceberg”. 
Many hidden functions were brought to light in the past decade which revealed the 
extraordinary versatility of such molecules.  
 Aiming to better understand and clarify the contributions of defensins to 
different pathways, Lehrer has published a review where he has summarised their role 
in host defense (Fig. 1.2) [58]. However, the diagram presented in figure 1.2 is non 
exhaustive as many new defensins implications have been recently described and 
some remain to be discovered. 
 
 












Figure 1.2. The multifaceted role of α- and β-defensins. Figure taken from Lehrer, 
2004 [58]. 
 
1.3 The Human β-Defensins 
 
1.3.1 Discovery and Isolation 
 
To date only four human beta-defensins have been characterised in detail despite 
evidence of more defensin genes (DEFB genes) in the human genome [59]. The first 
human defensin (HBD1) was described in 1995 and was isolated from 4800 litres of 
human hemofiltrate from patients undergoing hemodialysis for renal disease [60]. 
Purification of HBD1 required a combination of biochemical methods including batch 
extraction, semi-preparative reverse phase high performance liquid chromatography 
(RP-HPLC), and cation-exchange chromatography. The mature 36-residue peptide 
has been shown to be constitutively expressed in various tissues from different tracts. 
HBD1 is produced from human epithelial cells of mammary gland, parotid gland, 
small intestine, pancreas, testis, vagina, airways and many more [61-63]. Although 
HBD1 appears to be constantly produced in various tissues, its expression could also 
be mediated by inflammation or induced and upregulated by lipopolysaccharides and 
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interferon gamma (IFN-γ) [64, 65]. 
 HBD2, the second human defensin to be found, was isolated from 50 g of 
psoriatic scale skin [66]. The observation that patients with psoriasis were not more 
infected by pathogenic microorganisms despite the deteriorated aspect of the skin led 
the authors to the discovery and isolation of this 41-residue peptide. Unusually, HBD2 
was purified using an “Escherichia coli affinity” column where the bacteria were used 
to extract the defensins from a skin extract. Fractions displaying antimicrobial activity 
on plate were further purified by HPLC. After amino-acid sequence analysis of the 
peptide, results revealed a β-defensin consensus sequence with six conserved 
cysteines homologous to the previously identified HBD1 and the first described 
mammalian β-defensin, the tracheal antimicrobial peptide (TAP), isolated from cow 
tongue. HBD2 expression is found in keratinocytes and the gingival mucosa, but 
generally throughout the entire epithelial system [67, 68].  
 In 2001, a new β-defensin, the human β-defensin 3 (HBD3), was 
simultaneously described by three different groups [69-71]. In a similar manner to 
HBD2, HBD3 was isolated by Harder and coworkers from human lesional psoriatic 
scales and heel calluses using various chromatographic methods. The tissue extracts 
were applied to a Staphylococcus aureus affinity column and bound material further 
separated via a RP-HPLC system. Fractions displaying antimicrobial activity towards 
S. aureus were purified with a cation exchange HPLC column. Sequence analysis and 
mass spectrometry revealed the primary amino acid sequence of this novel peptide. In 
contrast to this biochemical approach, screening the human genome with the HBD1 
and HBD2 homologue genes led to the discovery of the HBD3 gene by two other 
research teams. 
 Similar processes were applied for the identification of the human β-defensin 4 
gene (HBD4) and consequently, HBD4 was synthesised using a chemical approach 
[72]. The synthetic HBD4 was assembled with protected amino acids from the C- to 
the N-terminus using a preloaded resin. So far, HBD4 has never been isolated and 
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1.3.2 Structural Characteristics  
 
The sequence alignment analysis of the most-studied β-defensins, HBD1 through 
HBD4 (Fig. 1.3 A), revealed that apart from 6 cysteines, only a few other amino acids 
are conserved within the sequence. However, a common trait shared by the four 
peptides, and more generally in all defensins, is their overall high content of positive 
residues, mainly lysine and arginine, leading to a cationicity ranging from +4 to +11. 
An additional remarkable similarity shared by human β-defensins is their tertiary 
structure. So far the structures of three human β-defensins have been solved by both 
NMR and X-ray crystallographic methods [73-77]. The first structure reported 
concerned HBD2 and was solved by X-ray crystallography (Fig. 1.3 B). 
Subsequently, structures of HBD1 and HBD3 followed shortly thereafter, and it 
appears that the core motif shared by the three peptides is a three β-strand motif 
disposed in an antiparallel sheet. This β-sheet fold is constrained by 3 intramolecular 
disulfide bridges and constitutes the “defensin-like” fold, which is the 3D “signature” 










Figure 1.3. A. Amino acid sequence and secondary structures of human β-defensins 
Number of residues and the formal charges are indicated. Six conserved cysteine 
residues are coloured in red, basic residues are highlighted in blue and anionic amino 






Chapter 1: Defensins 
12 
 Similarly to the α-class (which also contain 3 β-sheets), the β-defensins 
contain an α-helix of variable length at the N-terminus of the peptide. Of interest, in 
2003, Thouzeau and coworkers isolated two novel β-defensins, named spheniscins, 
from the stomach contents of the king penguin [78]. Subsequently, the NMR structure 
of the most abundant spheniscin, Sphe-2, was resolved and confirmed to be very 
similar to the human β-defensins displaying a β-sheet core and a N-terminal α-helix 
structural topologies [79]. 
 
1.3.3 Expression and Gene Regulation 
 
 Human β-defensins are expressed in various tracts and tissues throughout the 
body. However, their localisation and level of expression is highly variable from a 
peptide to an other. For example, HBD3 expression was shown to be elevated in tonsil 
tissue and keratinocytes but low in the epithelia cells of the genitourinary, respiratory, 
and gastrointestinal tracts. These observations were confirmed by Garcia and 
colleagues but additionally, they provided evidence of an expression in non-epithelial 
tissues such as skeletal and heart muscles or leukocytes [69]. High levels of HBD4 
expression was found in epididymis, testis and the gastric antrum. In contrast, low 
expression levels were reported from neutrophils, lung, kidney, thyroid gland and the 
uterus. The presence and possible role of HBD4 in human skin protection remain 
unclear as no expression in such tissue was demonstrated. However, and similarly to 
the other three β-defensins, HBD4 expression was induced in primary keratinocytes 
[80]. 
 Whilst HBD1 is a constitutively expressed peptide and displays relatively high 
and constant basal expression, the regulation of the expression of HBD2, HBD3 and 
HBD4 pathway appears to be distinct from HBD1. Indeed, HBD2-4 expression seems 
to be upregulated by proinflammatory stimuli or bacterial infection [66, 71, 72]. For 
each of these three defensins the induced expression was observed in various tissues 
and tracts including keratinocytes, dendritic cells, peripheral blood, respiratory and 
gastric epithelium. Moreover, stimulators such as LPS, TNF-α, interleukin-1β (IL-
1β), IL-1α, IFN-γ were also reported to induce their expression [81, 82]. Upregulation 
of HBD3 expression was also observed with induced factors such as insulin-like 
growth factor 1 (IGF-1) and transforming growth factor α (TGF-α) in human 
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keratinocytes [83]. Concerning HBD2 expression, its induction in various tissues was 
stimulated by bacterial components and cytokines via transcriptional nuclear factor 
κB (NF-κB) [84]. Moreover, evidence of upregulation for both HBD2 and HBD3 
expression by HIV-1 and Rhinovirus-16 in cultured bronchial epithelial cells was 
reported by Duits et al [85].  
 In the last decade, a distinct group of receptors have emerged, the toll-like 
receptors (TLRs), and have been shown to play a critical role in mediating defensins 
expression through various cells and tissues [86]. It is thought that both TLR-2 and 
TLR-4 modulate HBD2 expression in airway epithelia cells in response to bacterial 
components (e.g. LPS) [87, 88]. Despite increased knowledge concerning gene 
expression and regulation in the defensin field, it is obvious that the overall scheme of 
such mechanisms is very complex, and consequently far from being fully appreciated. 
This is due to the diversity of molecular mediators or partners involved, and the 
complexity of the various “branching” of the signaling pathways. 
 
1.3.4 Genes and Post-Translational Modifications 
 
In humans, defensin genes (DEFB genes) are mainly located on chromosome 8. 
However, four more conserved β-defensin gene clusters have been discovered and 
detected on chromosomes 6 and 20 [23]. Genes from the β-subgroup appear to have 
evolved characteristics, and common structures consisting of two exons separated by 
one intron. The first exon encodes a hydrophobic leucine-rich signal sequence, 
whereas the second exon encodes a short pro sequence and the peptide in its mature 
form. Post-translational proteolytic cleavages occur at the signal sequence and the 
propeptide sequence (Fig. 1.4). It results in the release of defensins in the immediate 
environment of cells expressing such peptides (e.g. epithelia). The processing 
enzymes for α-defensins pro-sequences in human and mice are respectively 
matrilysin and trypsin (human α-defensin 5) [89]. Concerning the β-subfamily, the 
enzymes responsible for proteolysis remain unknown although it was shown recently 
that matrilysin MMP-7 did catalyse the removal of six amino acids from the amino 
terminus of a 47-residue HBD-1 precursor [90]. 
 




Figure 1.4. Structure of prototypical defensin gene and peptide. The gene product is a 
prepropeptide where a pre-sequence encodes a peptide signal. The pro-sequence is 
cleaved by a specific protease to the mature peptide released.  
 
1.3.5 Antimicrobial Activity  
 
In two decades of discovery and characterisation of defensins, the antimicrobial 
properties of such peptides have been extensively explored. The crisis expected with 
the lack of new antibiotics has been exacerbated by the growing resistance of bacterial 
pathogens [91]. Consequently, this need has stimulated interest for such promising 
molecules. All four β-defensins characterised so far have been reported to inhibit or 
kill a broad range of microorganisms including fungi and bacteria. However, it 
appears that the scope of microbicidal activity differs across all of the peptides and 
their effectiveness is salt-sensitive [92]. In fact high salt concentrations inhibit 
antimicrobial activity of β-defensins. However, Yu and colleagues have overcome 
this problem by engineering a new circularised salt-insensitive peptide from an α-
defensin template [93]. HBD1 and HBD2 have been shown to be bactericidal against 
fungi and Gram-negative bacteria at µM concentrations, but were less effective 
against Gram-positive strains [59, 66, 94]. In contrast, HBD3 was reported to be a 
potent antibiotic against Gram-positive bacteria but also very effective towards Gram-
negative bacteria and yeast. More interestingly, HBD3 displayed its microbicidal 
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behavior in a salt-independent manner towards Staphylococcus aureus and the 
vancomycin-resistant Enterococcus faecium strains [71]. This antimicrobial ability is 
not true for HBD1, HBD2 and HBD4 as they were all inhibited at physiological 
concentrations of salt [72, 95]. Goldman et al. postulated that the inhibition of HBD1 
activity in patients with cystic fibrosis (CF) disease was due to high concentrations of 
salt in the airways of CF carriers. However, two reports have concluded otherwise 
stating that no difference in salt concentration was observed between healthy and CF 
patients [96, 97]. HBD4 was tested against Burkholderia cepacia, a pathogenic 
bacterium known for its ability to invade mucus found in the lung of cystic fibrosis 
patients, but weak microbicidal activity was observed (MIC>100 g/ml). In contrast, 
the peptide displayed a stronger activity towards Pseudomonas aeruginosa (MIC 4.1 
g/ml) [72]. In 2005, Chen and coworkers have highlighted the synergistic effect of 
an antimicrobial “mix” including HBDs (but not HBD4), cathelicidin LL37 and skin 
lysozyme towards E. coli and S. aureus. The authors demonstrated that the 
microbicidal effect of the mixture was enhanced compared to the single activity of an 
isolated peptide [98]. 
 
1.3.6 Structure-Activity Relationships 
 
Crystallographic studies of HBD2 have raised questions about the capacity for such 
peptides to form oligomers. A number of biophysical experiments revealed that the 
majority of the peptide was present as a dimer in solution, and this oligomeric form is 
favoured by the presence of the N-terminal α-helix. Moreover, this dimerisation 
phenomenon would allow the formation of a higher level of oligomerisation. In fact 
two different crystal forms have provided evidence for an octameric association by 
four noncovalent dimers [77]. The NMR study of HBD1, 2 and 3 by Schibli and 
coworkers demonstrated that HBD3 was the best candidate to form symmetric dimers 
in solution [75]. Therefore the authors concluded that this increased capacity to form 
dimers could be the reason for the enhanced bactericidal activity of HBD3 towards S. 
aureus in presence of a relatively high concentration of salt. Moreover, the high 
cationicity of HBD3 would be more advantageous compared to other β-defensins in 
order to overcome the decreased acidity in S. aureus membranes. However, further 
structural studies on this peptide have not permit to establish an explicit link between 
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HBD3 oligomerisation and antimicrobial activity. It was suggested that the high 
positive net charge coupled with a strong hydrophobicity pattern had more impact on 
the activity of HBD3 [99, 100]. The role of quaternary structure was explored in the 
case study of the mouse β-defensin-related 1 (Defr1) from our own laboratory, this 
provided new insights into structure-activity relationships of defensins [101]. Unlike 
other β-defensins, Defr1 displays 5 conserved cysteines instead of 6. The missing 
cysteine residue is the first one (from N-terminus) and is replaced by a tyrosine at 
position 5 in Defr1 sequence. Using high resolution mass spectrometry and tandem 
MS fragmentation techniques the authors showed that Defr1 forms a dimer held 
together by an intermolecular covalent bond. Thus the dimer contains 5 S-S bonds (4 
intramolecular and 1 intermolecular). The synthetic peptide used in the study was 
oxidised to form these S-S bonds but upon closer inspection it was revealed that Defr1 
dimer was a mixture of inseparable S-S bonded isoforms. To study the activity of the 
dimer, the authors engineered a Defr1 Y5C mutant possessing three disulfide bridges. 
This Defr1 Y5C oxidised to give a single isoform of β-defensin connectivity that was 
able to dimerise through noncovalent weak interactions only. Antimicrobial 
experiments demonstrated that the wild-type Defr1 S-S covalent dimer peptide was 
more potent than the Defr Y5C against Gram-negative and Gram-positive bacteria but 
also against the fungi C. albicans even under high salt concentrations. Interestingly, 
the reduced form of Defr1 was less potent against the same microorganisms in 
comparison to its oxidised form. These results have brought new knowledge with 
regards to the possibility of new targets for therapeutic purpose. 
 Originally, it was thought that the conserved cysteines among the defensin 
family played a crucial role in the antimicrobial activity of those peptides. Although 
these conserved residues are necessary for the maintenance of the triple stranded β-
sheet core and therefore the general folding of defensins, studies have shown that they 
did not influence their antibiotic ability. In 2003, Wu and colleagues showed that 
HBD3, unlike HBD1 and HBD2, did not fold to a single isoform under various 
oxidative conditions in vitro [102]. Topological analogues of HBD3, chemically 
synthesised, displayed the same antimicrobial aptitude towards E. coli despite 
different S-S bond connectivities. Unexpectedly, a mutated linearised HBD3 where all 
cysteines were replaced by α-aminobutyric acid (Abu-HBD3) exhibited the same 
killing activity but was also less salt-sensitive than the wild-type peptide. Moreover, 
Chapter 1: Defensins 
17 
the disulfide-devoid linearised HBD3 mutant did not chemoattract any of the tested 
cells expressing the GPCR chemokine receptor CCR6. They concluded that 
antimicrobial activity of HBD3 was S-S independent but chemokine activity required 
a folded peptide with 3 S-S bonds. This is unsurprising since the chemotactic activity 
surely relies on a protein/ligand interaction of high specificity. The same conclusions 
were drawn with the structural and biological studies carried out by Mandal et al. on 
the bovine neutrophil -defensin 12 (BNBD-12) and the α-defensin HNP1. These 
authors compared the antimicrobial activity of the peptides with analogues displaying 
one, two, three or different S-S bond topology. They concluded that the antimicrobial 
activity was independent of the location and the number of disulfide bridges [103, 
104]. A recent study by our laboratory has shed new light on the chemoattractant 
activity of HBD3 and Defb14 (the mouse ortholog of HBD3). Taylor et al. have 
confirmed that the chemoattractant activity was lost in a Defb14 derivative where all 
the cys residues had been replaced with alanine. However, activity was restored in 
peptides containing the cysteine at fifth position (cys5) [36]. They concluded that for 
these peptides, the presence of intramolecular disulfide bonds was irrelevant for both 
chemoattractant and antimicrobial activities and demonstrated that these two 
properties can be uncoupled. The authors also noticed that the antimicrobial activity 
was located at the N-terminal region of Defb14. The implication of the N-terminal α-
helical section was also linked to the antimicrobial potency of HBD2. In fact the 
orientation of this α-helix is governed by the aspartate residue at position 4. The lack 
of this residue in HBD2 resulted in a less structured peptide with less potent activity 
[105]. However, in a recent study, the peptide-membrane interactions were 
investigated with HBD2, HBD3 and analogues of these peptides. The authors reported 
that the β-sheet core appeared to be the primary structural element for membrane 
disruption while the α-helix would only modulate the antimicrobial activity [106]. 
This β-sheet core constrained by disulfide bridges, could also protect defensins from 
proteolytic cleavage by proteases [107]. 
 Despite all the reported evidence and the popularly admitted label of defensins 
as antimicrobial peptides, the molecular interactions within biological membranes and 
more generally the mechanisms of action and disruption of membranes are yet to be 
fully understood. Cationic antimicrobial peptides like defensins, exploit a 
physiological difference between microbial and eukaryotic membranes. Microbial 
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membranes tend to be negatively charged due to anionic components embedded 
within the lipid layer (cardiolipins, phosphatydilglycerol, lipotechoic acid and LPSs). 
In contrast, eukaryotic membranes possess a little net charge composed mainly with 
zwitterionic phospholipids such as phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE). 
 The first step of membrane-peptide recognition is carried out by electrostatic 
interaction. This phenomenon was first observed in the early 90’s where defensins 
were shown to be more effective against negatively charged membranes than neutral 
ones [108, 109]. It is not surprising that amphipathic defensins exploit their overall 
positive charge to bind bacterial membranes and then use their hydrophobic properties 
to penetrate deeper into it. However, the molecular mechanism for this phenomenon 
remains unclear and different models of permeabilisation of cells have been built up 
and described in an attempt to explain such mechanisms.  
 The “carpet model” depicts the formation of an extensive layer formed by 
accumulation of peptides bound to the membrane via electrostatic interactions (Fig. 
1.5 A). Peptides would cover the membrane bilayer in a carpet-like manner 
compromising its fluidity and displacing phospholipids until the membrane disruption 
[110]. This membrane deterioration mechanism is usually compared as a detergent-
like action. In the “carpet model” there is no requirement for the peptides to enter the 
hydrophobic environment or in forming quaternary structures. An alternative model, 
the “barrel-stave” model, describes the ability for antimicrobial peptides to form 
oligomers following the initial electrostatic interaction. This higher order of 
oligomerisation would allow peptides to form transmembrane pores causing leakage 
of the cell components (Fig. 1.5 B). The pore formation occurs after a concentration 
threshold where the peptide self-aggregates and enters deeper in the membrane [110]. 
 A third model was described and despite being another pore-formation model, 
it differs from the “barrel-stave” mechanism as the peptide is always associated to the 
lipids head-group so that the lipid monolayer bends continuously through the pore 
(Fig. 1.5 C). This model is called the “toroidal-pore” model [111].  
 Concerning β-defensins it is not clear what model is privileged with regards to 
their antimicrobial action, but it is possible that more than one can be adopted 
throughout the human defensin family. Although structural studies of HBD2 and 
human neutrophil peptides (HNPs) have provided evidence of oligomerisation, they 
Chapter 1: Defensins 
19 
resulted in a distinct approach concerning their antimicrobial action. Crystallographic 
studies of HBD2 have shown that the octameric oligomers found in some crystals 
adopted a flat disk shape privileging a mechanical action described in the “carpet” 
model [77]. In contrast, structural studies of HNP2 and HNP3 revealed that the 













Figure 1.5. The proposed models of membrane disruption by defensins. A. The 
“carpet” model. B. The “barrel-stave” model. C. The “toroidal-pore” model. Figure 
adapted from Brogden, 2005 [110]. 
 
 The models mentioned above depict the disruption of membrane cell walls and 
the lysis of cells, but there is increasing evidence that antimicrobial peptides can also 
target the intracellular components of cells. These secondary targets could include 
nucleic acids, glycoproteins, but also the inner membrane [45, 113]. This action 
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1.3.7 Mode of Production of Defensins 
 
The first human defensins to be discovered were extracted from their host 
environment e.g. blood or skin. Despite being a natural method of isolation there are 
many obvious problems related to such methods; the difficult availability of the 
tissues carrying the peptide but also the convoluted extraction steps followed by 
extensive purification and activity tests. Last, but not least, the product recovery is 
poor. HBD1 isolation from 4800 litres of human hemofiltrates led to 3 mg of peptide 
while only 200-400 µg of HBD2 were recovered from 50 g of psoriatic scales [60, 
66]. Moreover, the interesting discovery of the first β-defensin from king penguins 
has highlighted the laboriousness of such isolation. Spheniscins were extracted from 
60 ml of stomach contents from wild penguins [78].  
 Fortunately, different techniques allow the production of such peptides in a 
more convenient and efficient manner. Solid phase peptide synthesis is an efficient 
method which was developed in the 60’s by Robert Bruce Merrifield to produce small 
proteins and peptides [114]. This chemical approach has been developed for the 
production of several α- and β-defensins including HBD1 to HBD4. However, this 
method is limited by the amphiphilic nature of defensins and the cysteine-protection 
strategies lowering the overall yield of production [72, 102, 115, 116]. 
 The recombinant expression for defensins via a host organism has also been 
extensively used. Concerning defensins, an extra challenge has to be overcome due to 
the inherent antimicrobial activity of such molecules. Excess of mature soluble 
peptide within bacteria would impact severely on their viability. In order to avoid the 
toxicity of the peptide towards the host organism, a carrier protein is fused to the N-
terminal part of the target peptide. Usually this method uses an optimized easy-to-use 
Escherichia coli host strain for protein expression and purification but recently a 
different strategy using yeast as host organism was also developed [117, 118]. Over 
the past 10 years, various fusion partners including thioredoxin (trxA), green 
fluorescent protein (GFP) or light meromyosin (LMM) have been used to overcome 
the toxicity of defensins [119-121]. However, the cleavage of such fusion partners 
from the target peptide involves expensive proteases leading to substantial increasing 
cost. In 2006, Pazgier and colleagues succeeded in the preparation and analysis of 26 
site-specific, single-change HBD1 mutants [122]. This tour de force led to the 
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determination of X-ray crystal structures of 14 of the mutants. The authors used a 
tryptophan operon sequence as a fusion-tag and the proteins were produced within E. 
coli as inclusion bodies. A recent emerging method using a cell-free system (cell-free 
extracts) was used for the production of HBD2 [123]. This method allows an in vitro 
protein expression and purification using the bacterial machinery from cell extracts 
and a DNA plasmid. Tomas Ganz and coworkers produced HBD1, HBD2 and various 
defensins with a recombinant baculovirus-infected insect cell system [124-127].  
 The isolation and different mode of productions of human beta-defensins are 
summarised in the following Table 1.2.  
 In this thesis, a method for the recombinant production of a mature, bioactive, 
single isoform of HBD2 and isotopically labelled 15N-HBD2 in E. coli is presented. 
The method described is straight-forward, low-cost and leads to the production of 
pure oxidised and folded HBD2 in milligram quantities [128, 129] (see papers 
attached in Appendix). The peptide was characterised by various structural techniques 
and displayed excellent structural properties suitable for further investigation of 














































































































   


































































































































































































































































































































































































Table 1.2. Discovery and tissue isolation of the human beta-defensins. The three 
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2.1 Cloning of HBD2 
 
The HBD2 gene was synthesised using six overlapping primers with codons 
optimised for expression in E. coli. The PCR product containing the codon-optimised 
gene preceded by a methionine was then ligated into the expression plasmid pET-31b 
(Novagen) and named pET-31b/HBD2. This plasmid was then used to express an 
insoluble ketosteroid isomerase (KSI) tag upstream HBD2 gene. The idea behind the 
insoluble-fused tag cloning was to knock-out the antimicrobial activity of such a 
peptide which would considerably affect the expression process. Therefore, KSI-
HBD2 species was expressed as inclusion bodies. The pET-31b plasmid contained a 
tandem repeat unit of the HBD2 gene which renders any future preparation of HBD2 
mutants difficult. Therefore to prepare an expression construct with a single HBD2 
gene the KSI/HBD2-fusion fragment from pET-31b/HBD2 was isolated and ligated 
into a pET-28a(+) (Novagen) in order to introduce a N-terminal His(6)-tag sequence. 
Furthermore, to avoid multiple cleavage sites with CNBr, two methionine residues 
were replaced by two alanine using site-directed mutagenesis in the KSI sequence to 
give the pET-28a/HBD2 plasmid (Fig. 2.1). This process was carried out in 










Figure 2.1. The pET-28a/HBD2 plasmid used for the production of HBD2. 
 
 Both vector constructs (pET-31b/HBD2 and pET-28a/HBD2) were used in 
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2.2 Overexpression and Purification of KSI-HBD2 Fusion Protein 
 
The aim of this project was to develop a suitable method for the production of a single 
isoform of biologically active, oxidised β-HBD2 in a reproducible and efficient 
procedure of high analytical purity.  
The first plasmid used for the expression and purification was pET-
31b/HBD2. E. coli BL21(DE3) competent cells were transformed with the plasmid 
and a growth of 3 L culture was routinely used. The cells were induced with IPTG for 
several hours which allowed them to reach a high level of expression of inclusion 
bodies. The expression was monitored by SDS-PAGE gel (Fig. 2.2). A strong band 
corresponding to KSI-HBD2 at around 17.5 kDa was observed in both non-induced 
and induced sample (Fig. 2.2.A). Since expression was observed in the non-induced 
sample we concluded that the control of expression was “leaky”, but this did not 
influence the growth of the cells and subsequent yield of the fused-HBD2 expression. 
  
 
Figure 2.2. Expression of KSI-HBD2. A. before and after induction with IPTG (lanes 
1 and 2). B. Purification (lane 1) and CNBr cleveage (lane 2) of KSI-HBD2. 
 
Cells harvested by centrifugation were lysed by treatment with lysozyme and 
freeze-thawing. The inclusion bodies were furthermore purified with a series of 
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2.3 CNBr Cleavage of KSI-HBD2 Fusion Protein and Purification of HBD2 
Using a Fast Protein Chromatography Liquid (FPLC) System 
 
The solubilisation step of inclusion bodies with guanidine was followed by cleavage 
with CNBr. The last wash and subsequent cleavage of the inclusion bodies in their 
soluble form by CNBr cleavage was visualised on the SDS-PAGE gel (Fig. 2.3, lane 1 
and 2). A remaining band at around 18 kDa corresponding to uncleaved KSI-HBD2 
can be observed in addition to the cleaved products KSI (13.5 kDa) and HBD2 (4.5 
kDa). Due to the highly insoluble properties of the KSI amino acid sequence, the 
unwanted products KSI-HBD2 and KSI were removed after precipitation in a single 
step dialysis resulting in a crude soluble HBD2 sample, which remained in the 
supernatant (see SDS-PAGE analysis in figure 2.3, lane 3). 
 
Figure 2.3. SDS-PAGE of the crude HBD2 (lane 3) soluble fraction after CNBr 
cleavage (lane 2). 
 
 Initial attempts to purify the peptide from the crude soluble extract after 
cleavage and separation of the insoluble fraction were realised by the use of a strong 
cationic exchange column attached to an AKTA Fast Purification Liquid 
Chromatography system (FPLC). After purification, the sample was concentrated and 
injected onto Mono S 5/50 GL (Amersham Bioscience) a strong cationic exchange 
column. Ten mls of the sample was injected at 1 mg/ml and eluted with a linear 
gradient from 0% to 100% NaCl 1 M (Fig. 2.4). Fraction 16 which corresponds to the 
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fraction 16 is 4327.9 ± 0.07 Da which is in agreement with the predicted mass of 
4328.02 Da for the oxidised HBD2 (Fig. 2.5). Analysis of fractions 14 and 15 by LC-
ESI-MS revealed a mixture of partially oxidised peptide with adducts (data not 
shown). The final peptide concentration calculated with the BCA assay was ~300 g 








Figure 2.4. Elution profile of crude HBD2 by FPLC. Fraction 16 (outlined) was 








Figure 2.5. ESI mass spectrum of HBD2 from fraction 16 (Fig. 2.4). The ion envelope 
of the peptide shows the +5 (m/z 866.57), +4 (m/z 1082.93) and +3 (m/z 1443.53) 
charge states. 
 
 Despite positive results obtained with this protocol, the method proved to be 
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remained low. Actually, the FPLC profile of the eluted sample with a clean peak 
corresponding to a pure oxidised peptide was difficult to reproduce. Many attempts 
resulted in a mixture of peptides with adducts leading to a heterogeneous sample. At 
this stage of the project it was necessary to adopt a new strategy using an optimised 
plasmid and another purification system. We decided to replace the FPLC system 
with an HPLC system with a reverse-phase column which would give a better product 
separation. Moreover, the optimised plasmid pET28a/HBD2 was thereafter the 
expression plasmid used. 
 
2.4 Expression and Purification of HBD2 Using the pET-28a/HBD2 
Plasmid and an HPLC System 
 
The expression and purification protocol until the last wash and solubilisation of the 
inclusion bodies remained the same as previously described (see chapter 3.3). After 
the solubilised solution was mixed with nickel resin, the HisKSI-HBD2 fusion protein 
was eluted and monitored by SDS-PAGE (Fig. 2.6). A band at around 20 kDa was 
observed corresponding to the predicted molecular weight of the HisKSI-HBD2 
fusion protein of 189aa. The eluted protein was then cleaved by CNBr and the 
unwanted KSI fragments precipitated by dialysis. After a centrifugation step, the 
supernatant containing the soluble fraction was extracted and analysed by SDS-PAGE 
(Fig. 2.6 lane 3). 
 
 
Figure 2.6. Elution profile of HisKSI-HBD2 monitored by SDS-PAGE (lane 1). The 
sample was cleaved by CNBr (lane 2). Lane 3 shows the crude soluble fraction of 
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 An HPLC system with a reverse-phase semi-preparative C18 column was used 
to purify the crude extract from the supernatant. The sample was reduced with an 
excess of TCEP (tris(2-carboxyethyl)phosphine), concentrated and loaded onto the 
column. The HPLC chromatograph profile of the eluted crude sample is represented 
in figure 2.7. The gradient used was 5-55 % acetonitrile over 50 minutes. Although 
this chromatograph profile could change from one preparation to another, peaks 
eluted between 32-34 minutes were always present at this stage of the purification 
(Fig. 2.7 outlined in red). 

Figure 2.7. Reverse-phase HPLC chromatogram of the crude sample reduced with 
TCEP. Peaks outlined in red were extracted and further analysed by ESI-MS. 
 
 These peaks were collected manually and analysed by direct injection ESI-
MS. This analysis gave the molecular weight of the peptide as 4334.1 ± 0.12 Da 
which is in good agreement with the predicted value of the reduced HBD2 defensin: 
4334.0 Da (data not shown). A second run of HPLC was used when a higher purity of 
the reduced peptide was needed. 
 
2.5 Refolding of the Recombinant Defensin 
 
Once the peptide was purified in its fully reduced form, a freeze-drying step was 
required in order to obtain the peptide in a lyophilised form. Reduced HBD2 was then 
resuspended in a cysteine/cystine (10:1) redox buffer for 2-3 hours. The refolding 
reaction was terminated with an excess of TFA and the sample was reinjected into the 
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semi-preparative C18 column. The peptide was eluted with the same gradient 
described for the crude sample (Fig. 2.8).
 
Figure 2.8. Reverse-phase HPLC chromatogram of HBD2 after the refolding reaction. 
The peak eluted at 34 min. was extracted, monitored by SDS-PAGE (inset) and 
analysed by direct injection ESI-MS. 
 
 After the refolding step, the HPLC elution profile showed a sharp clean peak 
at a retention time of 37 minutes. This species was eluted 5 minutes after the reduced 
peptide (32 minute). The 37 minute peak was collected and was analysed by ESI-MS 
which showed a convoluted mass of 4328.1 ± 0.7 Da which is in agreement with the 
predicted mass of 4328.0 Da which corresponds to the oxidised peptide form (Fig. 
2.9). The average recovery of oxidised peptide over the fully reduced starting material 
lies between 50% and 80%. The yield of pure oxidised peptide, calculated with the 
BCA assay for at least 10 preparations, was between 3 to 6 mg from 3 litres of 
bacterial culture. 
 Despite the fact that the observed mass (4328.1 ± 0.7 Da) matched the 
theoretical mass (4328.0 Da) of oxidised HBD2 it was necessary to check if the 
sample was fully oxidised (no cysteine in the reduced form). To analyse the oxidation 
state of the peptide, HBD2 was incubated with iodoacetamide, a compound which 
reacts with free thiol groups of cysteines. The iodoacetamide-modified peptide yields 








  M 










Figure 2.9. ESI mass spectrum of HBD2 from fraction eluted at 37 minutes (Fig. 2.8). 
The ion envelope of the peptide shows the +5 (m/z 866.6), +4 (m/z 1083.0) and +3 
(m/z 1443.5) charge states. 
 
 After the reaction, the sample was analysed by LC-ESI MS and the 
deconvoluted major peak at 4328 Da corresponding to the oxidised form was 
observed (Fig. 2.10). In addition, peaks at 4385 and 4442 Da were also present. These 
peaks correspond to an increased mass of 57 Da and 114 Da (2 X 57 Da) compared to 
the unmodified peptide. Obviously only a very small amount of the peptide is partially 
modified as the major peak still remains at 4328 Da. The increased mass of 57 Da 
could be due to iodoacetamide adducts at the N-terminal of the peptide. This assay 
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Figure 2.10. ESI mass spectrum of HBD2 incubated with iodoacetamide. 
Deconvoluted masses indicate that HBD2 is in its complete oxidised form as the 
major peak is observed at 4328.0 Da. 
2.6 Determination of Disulfide Connectivity for HBD2 
 
The level of oxidation does not explain the S-S connectivities between cysteine 
residues in HBD2, which are Cys1-Cys5, Cys2-Cys4 and Cys3-Cys6 in a folded β-
isoform of the peptide. To verify whether HBD2 is folded correctly a digestion with 
trypsin and chymotrypsin was performed and analysed by ESI-MS. Fragments 
cleaved by both proteases were initially predicted with PAWS software (The Protein 
Analysis Worksheet). The different steps of proteolysis and the final reaction with 
Edman’s reagent are shown in figure 2.11. The predicted mass of each fragment is 
also indicated. 
 
Figure 2.11. Proteolysis and Edman degradation of HBD2. The peptide was first 
digested by trypsin and chymotrypsin. Edman’s reagent was then used to verify the S-
S bond connectivities between cysteine residues Cys1, Cys3, Cys5 and Cys6. 
 
After digestion with trypsin and chymotrypsin the sample was analysed by 
LC-ESI MS. Two peaks showing masses at 1002 Da and 799 Da were detected (Fig. 





[IGDPVTC1L]        [
PTHC5] 1054 Da 
   
[PTHC3]        [C6K] 486 Da 
GIGDPVTC1L   C5C6K   C3PR 
Predicted mass: 1595 Da 
SGAIC2HPVF   QIGTC4GLPGTK 
2002 Da 
Edman degradation 
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2.12 A, 1 and 2) which upon deconvolution represent masses respectively at 2002 Da 
and 1596.0 Da (Fig. 2.12 in red numbers). These observed masses were in agreement 
(± 1 Da) with the predicted ones according to PAWS software. However, an extra step 
was needed to segregate what S-S connectivities were contained in the fragment with 
cysteine residues Cys1, Cys3, Cys5 and Cys6. At this stage only the Cys2-Cys4 
connection was confirmed, but it was impossible to assign the other disulfide bonds as 
two possibilities remain; Cys1-Cys5 and Cys3-Cys6 or Cys1-Cys6 and Cys3-Cys5. After 
the first digestion with trypsin and chymotrypsin the fragment of mass = 1596 Da was 
extracted and submitted to an Edman degradation. With this method, the amino-
terminal residue is chemically modified to generate a phenylthiohydantoin (PTH) 
adduct and then cleaved from the peptide. After the reaction, the derivatised 
fragments were reinjected and analysed by LC-ESI-MS. The mass spectrum analysis 
revealed a deconvoluted peak at 1055 Da (Fig. 2.12 B). This mass corresponds to the 
fragment containing cysteines 1 and 5 with a predicted mass of 1054 Da. 
The proteolysis of the oxidised peptide plus an additional step of Edman 
degradation led us to believe that HBD2 was folded in the typical β-defensin disulfide 
bond connectivity: Cys2-Cys4, Cys1-Cys5 and Cys3-Cys6. 
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Figure 2.12. Analysis of the S-S bond connectivities in HBD2 by ESI-MS. Fragments 
generated by proteolysis and Edman degradation are shown respectively in section A 
and B. Deconvoluted masses are represented with red numbers. 
 
2.7 Structural Characterisation of Mature -Defensins 
 
The structure of synthetic HBD2 has been determined using NMR and X-ray 
crystallography and both methods gave essentially the same results [74, 77]. To 
investigate our own structural studies of HBD2 complexes we began by analysing if 
the purified oxidised recombinant material was suitable for NMR studies. NMR data 
collection was carried out at pH 3.7 at a peptide concentration of 0.6 mM. A 2D-
[M+2H]2+  
1055 Da 
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TOCSY spectrum was obtained after scanning for 2 h 30 min. (Fig. 2.13). The 
outlined region (in red) between 7 and 10 ppm contains the amide protons which are 
exposed to solvent exchange faster than those which are buried or form stable 
hydrogen bonds. This method exploits the constant exchange of peptide backbone 
amide protons with solvent protons to evaluate protein structure, stability and 
dynamics. By looking in the 6-10 ppm region, we can get information about whether 
the peptide is folded or not. The 1D 1H NMR spectrum shows sharp and distinctive 
peaks in the amide region while the 2D 1H NMR spectrum details well-dispersed 





















Figure 2.13. 1D 1H NMR and 2D 1H NMR spectra of oxidised HBD2. The amide 
region outlined in red is indicative of a folded structure. 
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2.8 Expression, Purification and Characterisation of the 15N Labelled-
HBD2. 
 
Once a valid method was obtained for the isolation of the mature HBD2 peptide, we 
thought it would be interesting and very valuable to purify an enriched version of 
HBD2 by incorporation of a nitrogen-15 (15N) label into the peptide. This isotope is 
frequently used in nuclear magnetic resonance spectroscopy (NMR). Unlike the 
abundant isotope nitrogen-14 (99.634%), 15N has a nuclear spin of ½, which can be 
observed by NMR. So far all NMR-defensins structural studies involved the use of 
natural isotope 1H NMR which can be problematic for binding studies due to 
overlapping signals. The interaction of such peptides is facilitated if all the amino acid 
can be assigned distinctively. 
 The main changes concerning the production of the 15N HBD2 concern the 
expression step. Briefly optimised growth conditions involving a defined mixture of 
trace metals and 15N-ISOGRO (available from Sigma) in a M9 minimal medium 
was used (Chapter 6, section 6.1.1.3). The isolation, purification and folding steps 
used were similar to those described previously in this chapter. 
 The protein expression system used the E. coli strain BL21(DE3)plysS freshly 
transformed with pET-28a/HBD2 plasmid. After induction with IPTG the inclusion 
bodies were washed, further purified and chemically cleaved as mentioned before for 
the unlabelled HBD2 (Fig. 2.14 lane 2 to 4). After precipitation of undesired insoluble 
fragments, the reduced crude soluble preparation was monitored on SDS-PAGE gel 
(Fig. 2.14 lane 5) and injected onto a semi-preparative C18 column attached to a 
HPLC system. The different crude fractions were collected, analysed by direct 
injection ESI-MS (Fig. 2.15) and selected for the reduced enriched peptide. Analysis 
of the sample by ESI-MS revealed, after deconvolution, that a major species was 
present with a 4389.0 ± 0.1 Da mass which is in agreement with the theoretical mass 
of fully reduced peptide based on the mature 15N-incorporated HBD2 sequence 
(GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP) lacking all 
disulfide bonds (calculated mass 4388.5 Da). 
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Figure 2.14. The different step of expression and purification of 15N HBD2 monitored 
by SDS-PAGE. Lane 1 and 2 represent respectively the cell extracts before and after 
induction with IPTG. Inclusion bodies were solubilised (lane 3) and the KSI tag 
cleaved by CNBr (lane 4). The insoluble fraction was removed and soluble crude 




Figure 2.15. Analysis by ESI-MS of the reduced labelled-HBD2 shows an ion 
envelope with four charge states; +6 (m/z 732.5), +5 (m/z 878.8), +4 (m/z 1098.6), 
and +3 (m/z 1464.4). Picture of reduced lyophilised sample is shown in insert. 
 
 A lyophilised sample was resuspended in the cysteine/cystine redox (10:1) 
buffer for few hours. Both reduced and oxidised labelled-HBD2 were monitored by 
reverse phase-HPLC (Fig. 2.16) and analysed by high resolution nanoelectrospray FT-














Figure 2.16.HPLC chromatogram of the oxidised and reduced form of 15N HBD2. 
Analysis was performed on a C18 reverse phase HPLC column using a 5-55% 
acetonitrile gradient over 50 minutes. The oxidised form is eluted 4 to 6 minutes after 
the reduced species. 
 
 The FT-ICR MS analysis of 15N labelled HBD2 shows an ion envelope 
containing three charge states ([M+5H]5+, [M+4H]4+, [M+3H]3+). After 
deconvolution, the average mass of the oxidised 15N HBD2 was 4382.5 Da (Fig. 2.17 
red) which is in good agreement with the theoretical mass of the fully oxidised 
peptide based on the amino acid sequence with three S-S bonds. The oxidised form of 








Figure 2.17 displays the mass spectra of labelled (red) versus the unlabelled (black) 
peptide. Upon deconvolution the masses of the two species differ by 55 Da validating 
























Figure 2.17. FT-ICR high resolution mass spectrum of oxidised 15N HBD2 (red) 
versus oxidised 14N HBD2 (black) showing the +6 (m/z 722.2/730.8), +5 (m/z 
866.6/877.4), and +4 (m/z 1082.8/1096.3) charge states. The deconvoluted mass of 
15N HBD2 was calculated at 4382.5 Da. 
 
 In order to evaluate the full potential of Nitrogen-15 incorporation, it was 
necessary to obtain the NMR spectra of the peptide. Previous work on NMR structure 
of unlabelled HBD2 reported the use of phosphate buffer at pH 3.7 and 6.4 [74]. Data 
collected at pH 3.7 gave spectra with better resolution despite working outside the 
range of the buffer (pH 6-13). In this study, an acetate buffer was used in order to 
apply the desired acidic pH in accordance with its buffer range (pH 3.8-5.8). The 
solution was adjusted to pH 4.7 and the NMR spectrum obtained has a much 
improved spectral resolution. Figure 2.18 shows the 1D 1H NMR spectra of 
unlabelled HBD2 versus its 15N labelled version in the amide region. 
 Similarly to 14N HBD2, the 15N HBD2 amide region shows well-dispersed, 
sharp peaks corresponding to a defined folded structure. However, as notified on 
figure 2.18, if the chemical shifts within the amide region remain the same, each 
resonance peak is split into a doublet in the labelled sample. This phenomenon is due 
to the 1J (15NH) coupling. While the data used to solve the NMR structure of HBD2 
(biological Magnetic Resonance Data Bank, PDB file 1fqq) [74] contained several 
overlapping amide proton chemical shifts, the 2D 1H-15N HSQC spectrum in figure 
2.19 shows distinctive chemical shifts and unambiguous identified amino acids (the 
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6+
8 6 6 .6
5 +
10 8 2 .8
4+
8 7 7 .4
5 +
1 0 96 .3
4 +







Chapter 2: Expression, Purification and Characterisation of HBD2 
40 













Figure 2.18. The amide region of the 600 MHz 1D 1H NMR spectra of 14N and 15N 


















Figure 2.19. 2D 1H–15N HSQC spectrum (600 MHz) of 0.23 mM 15N labelled HBD2 
in 20 mM sodium acetate buffer at pH 4.7 and 25 oC. The sequence is given above the 
spectrum. The side chain amide cross peaks of residues 22R, 23R and 26Q are circled. 
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2.9 Antimicrobial Properties of HBD2 
 
In order to evaluate the antimicrobial activity of the mature peptide it was necessary 
to test its antibiotic properties towards diverse microorganisms. We selected four 
strains including two Gram-negative bacteria, Escherichia Coli (K-12, MG1655), 
Pseudomonas Aeruginosa (PAO1) and one Gram-positive bacteria Staphylococcus 
aureus (ATCC 25923). We also tested the peptide against a fungus, Candida albicans 
(J2922). The antimicrobial assay consisted of incubating different concentration of 
peptide against a fixed concentration of the microorganism in a method used 
previously in the lab [101]. Two sets of plates were used; one was spreaded with the 
undiluted sample and the other was spreaded a 100-fold diluted sample. Each plate 
was counted and the results were processed in order to calculate values for the 
minimum bactericidal concentration at 99.99% (MBC99.99). Briefly, we have 
determined the concentration of peptide where we observed >99.99% killing of the 
initial inoculum. The same principle was applied to determine the LD90 and LD50 
values (Lethal Dose: amount of peptide required to kill 50% and 90% of the initial 
inoculum).  
 As a positive control we tested a well-studied cAMP antibiotic, Polymyxin B, 
towards the same organisms. The results are summarised in the Table 3 1. All 
experiments were performed at least 3 times for each strain and the mean of each was 
calculated. 
 
Table 3 1. Antimicrobial Activity of HBD2 against different organisms (Values are in 
µg/mL, PMB: Polymyxin B as Control AMP). 
 
Organism  Type MBC99.99 LD90 LD50 
E. coli K12-MG1655 Gram-negative <20 
(<1.5, PMB) 
3-6 <1.5 










C. albicans J2922 Fungus >50 
(<3, PMB) 
>6 >1.5 
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 Killing assay results showed that HBD2 exhibited broad spectrum 
antimicrobial activity, with MBCs lower than 25 M against the Gram-negative 
bacteria (Escherichia coli and Pseudomonas aeruginosa). Moreover HBD2 also 
displayed antifungal activity against Candida albicans in the µM range. All LD90 
values were observed below 10 µM with the exception of Gram-positive 
Staphylococcus aureus where HBD2 had a lower bactericidal effect as previously 
observed by Harder and colleagues [66]. They observed that natural HBD2 isolated 
from psoriasis scales achieved only bacteriostatic effect on S. aureus at concentration 
as high as 100 µg/mL. 
 Concerning the antimicrobial activity of Polymyxin B, MBCs values did not 
exceed 6 µM for any of the strains used. 
 
2.10 Surface Plasmon Resonance (SPR) Binding Studies of HBD2 with 
Biological Membrane Models. 
 
In this study we investigated the binding properties of HBD2 with different vesicles 
using the technique of surface plasmon resonance (SPR). Briefly, SPR is a 
phenomenon that occurs at an interface between media of different refractive index. 
SPR-based instruments use an optical method to measure this refractive index near a 
sensor surface. In the BIAcore system (the most widely used SPR-based instrument), 
the sensor surface (a chip) forms the floor of a small flow cell, through which an 
aqueous solution passes under a continuous flow (Fig. 2.20 A). To detect an 
interaction, a molecule (ligand) is immobilised onto the chip and its binding partner 
(the analyte) is injected in aqueous solution through the flow cell. When the analyte, 
also injected through a continuous flow, binds to the ligand, a response is observed 
resulting in an increase in the refractive index. This difference in refractive index is 
measured and monitored in real time on a sensorgram (Fig. 2.20 B). The results are 
plotted as time versus response which is measured in response units (RU) and is 












Figure 2.20. The BIAcore biosensor technology (A). Interaction between analytes and 
ligands are monitored on a sensorgram (B). On the sensorgram are indicated the 
different phases of a binding curve (I. baseline, II. association, III. dissociation, IV. 
regeneration). 
 
 BIAcore studies were performed with purified recombinant HBD2 in its 
oxidised form. Three different types of large unilamellar vesicles were formed by 
lipid extrusion through a 100 nm extruder. The first type of vesicles coated on the L1 
chip was the pure POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) 
vesicles. A second cell was coated with the POPC/POPG (POPG: 1-palmitoyl-2-
oleoyl-sn-glycero-3-phospho-(1'-sn-glycerol) (7:3) vesicles and finally the third cell 
was coated with the POPE/Kdo2-lipid A (10:1) vesicles. The choice to mix POPE 
with Kdo2-lipid A instead of POPC was motivated by a recent paper where the use of 
POPC with the deep-rough LPS led to heterogeneous quarternary structures 
undesirable for vesicle preparation [131]. Those aggregates were not observed for 
POPE/Kdo2-Lipid A mixture. The vesicle capture sensor chip L1 has dextran 
modified (liphophilic anchors) matrix molecules on the surface that allow binding of 
liposomes to mimic a fluid bilayer membrane. SPR sensorgrams monitor the strength 
of association and dissociation on the chip surface with AMPs. 
 The aim of this study was to investigate the interaction of HBD2 with different 
type of membranes. The pure POPC vesicles generate zwitterionic membranes 
whereas POPC/POPG (7:3) and POPE/Kdo2-lipid A (10:1) vesicles share both 
negatively charged membranes. Moreover, the introduction of the deep-rough LPS 
(Kdo2-lipid A) from E. coli into the phospholipidic membranes presented a model 
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onto the L1 chip gave a response higher than 10000 RUs (data not shown). This 
response, once normalised, constitutes the starting baseline for the binding 
experiments (Fig. 2.20. B, I). 
 Peptides were injected to the three lipid systems at concentrations of 1.25, 2.5, 
5, and 10 µM. The sensorgrams representing the binding curves of HBD2 to each 
lipid system are shown in figure 2.21. It is interesting to note that the same binding 
kinetics is observed for the three different types of membranes. In addition, the 
peptide concentration was proportional to the response monitored on the sensorgram. 
For each lipid composition, HBD2 demonstrated an increase in the initial binding 
with a saturation level observed from 25 seconds to less than 5 seconds.  
 Concerning the mixed POPC/POPG membrane model, the response for each 
of the different concentrations of peptide injected was higher compared to the binding 
with zwitterionic vesicles (Fig. 2.21, A and B). The differences between the values 
from sensorgram B to A are ranged from 50 RUs (1.25 µM) to 100 RUs (10 µM). 
This difference in the affinity was expected as positively charged peptides are 
attracted to negatively charged membranes. When compared to the mixed 
POPE/Kdo2-lipid A vesicles, these differences are even more pronounced ranging 
from 200 RUs (1.25 M) to 400 RUs (10 M). Despite the identical overall negative 
charges shared by the two membranes it is interesting to notice the threshold in the 
binding response between these two models. The incorporation of the deep-rough LPS 
into the membrane confers a stronger affinity towards HBD2 than the POPG-
incorporated phospholipids suggesting a possible role for Kdo2-Lipid A in the 
membrane disruption process when Gram-negative bacteria are challenged by 
cAMPs. 
 After the peptide injection (time ~ 200s) the dissociation curves show a slower 
rate compared to the association curves. The time observed for dissociation is 
between 150 and 300 seconds with the slower rate observed for the POPE/Kdo2-lipid 
A vesicles. The contrast between the two phases could be explained by the fact that 
the peptides penetrate deeper into the membrane bilayer. It is postulated that the initial 
interactions between cationic antimicrobial peptides and anionic bacterial membranes 
are electrostatic in nature. Thereafter the hydrophobic properties of defensins force 
the peptides to penetrate deeper into the membrane and interact with the fatty acid 
chains of the lipids. Thus the time required for the removal of peptides is higher than 
the time required for their electrostatic binding. 























Figure 2.21. SPR sensorgrams of HBD2 interactions with POPC, POPC/POPG (7:3) 
and POPE/Kdo2-Lipid A (top to bottom) membrane systems. Concentrations of 
HBD2 and axis units are indicated in the inset.  
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In this study, two different methods were used to produce HBD1. A chemical 
approach was employed via the solid-phase peptide synthesis (SPPS) method in 
collaboration with Dr. Derek Macmillan (UCL, London). Then a second approach 
using the recombinant method as previously described (Chapter 2) was tested.  
 
3.1 Solid-Phase Peptide Synthesis (Attempt) of HBD1. 
 
Solid-phase peptide synthesis (SPPS) is highly convenient for natural peptides which 
are difficult to express in bacteria. Therefore its use for the synthesis of antimicrobial 
peptides such as defensins was tested as an alternative method of peptide production. 
 The general principle of SPPS is the construction of a peptide chain from the 
C-terminus to the N-terminus. The C-terminal amino acid residue is attached to an 
insoluble solid support via its carboxyl group while its N-terminus is protected by a 
group (Boc or F-moc). The targeted peptide is built-up by repeated cycles of 










Figure 3.1. Chemical structure of the resin used for the synthesis of HBD1. The 
location of the starting lysine residue on the resin and within the HBD1 sequence is 
indicated in red circles. 
 
 The mature HBD1 is a 36 amino acid peptide with a lysine residue at the C-
terminus (Fig. 3.1). The theoretical mass of the reduced peptide (6 free thiols) is 
3934.1 Da. In order for the reaction to proceed from C-terminus to N-terminus the 
starting material used was a Fmoc-Lys(Boc)-NovaSyn® TGT resin (Fig. 3.1) where 
the first C-terminal amino acid is a lysine protected with a F-moc group. 
 The synthesis of HBD1 was performed in two steps; the first half was 
synthesised (36th to 19th amino acids) and the process analysed by ESI-MS. After the 
Lys 
Chapter 3: Synthetic and Recombinant Production of Defensins 
48 
first half synthesis, four major species were observed including the correct fragment 
of HBD1 of 2049.6 Da (2048.4 Da for calculated mass) which at this stage remains 
the major species (data not shown). However, after the second half synthesis, an RP-
HPLC column was used to analyse the crude product (Fig. 3.2). The chromatograph 
profile of the crude product shows several overlapping peaks. Analysis by LC-ESI-
MS confirmed the complexity of the crude sample and the full length HBD1 was 
difficult to detect. Therefore the isolation of the peptide from other truncated or larger 
fragments remained improbable.  
 
Figure 3.2. Chromatogram of crude HBD1 after the attempt of the full peptide 
synthesis.  
 
 A second chemical synthesis of HBD1 was attempted. We decided to fractionate 
the synthesis in 3 equal parts of 12 mers each. The fragment containing the first 
twelve amino acids from the C-terminus was synthesised without any technical 
difficulty leading to one main species. However, synthesis of the subsequent twelve 
amino acid segment proved unsuccessful. The errors in the synthesis could be caused 
by a sequence of hydrophobic amino acids. This hydrophobic patch is located in the 
middle of the amino acid sequence and could involve the following sequence: 
ACPIFTKI (Fig. 3.1). This hydrophobic sequence tends to make the accessibility 
harder for the coupling of other amino acids.  
 There are reports in the literature of the preparation of HBD1 using SPPS [102, 
132], but in these reports no mention is made of any technical difficulties 
encountered, or indeed in any problems with obtaining full length product. As a result, 
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and since our recombinant method has shown success in generating HBD2, we 
decided to abandon the synthesis of HBD1 in favour of a recombinant method.  
 
3.2 Recombinant Expression and Purification of HBD1  
 
A codon-optimised, synthetic HBD1 gene was purchased from CLONTECH and 
cloned alongside with the HisKSI sequence in the pUC19 vector. The HisKSI-HBD1 
fragment was cloned into the pET28a vector using NcoI and XhoI restriction sites. 
We used the pET-28a/HBD2 plasmid as template and replaced the HisKSI-HBD2 
sequence with KSI-HBD1 to finally generate the pET28a/HBD1 plasmid (not shown). 
The method of expression and purification used was similar to the method described 
in Chapter 2. HBD1 was expressed as inclusion bodies due to the highly insoluble 










Figure 3.3. Purification steps of HBD1. HisKSI-HBD1 fused peptide was solubilised 
(lane 1) before being cleaved (lane 2). The crude fraction containing HBD1 after 
precipitation is shown on lane 3. 
 
 The last steps of purification and cleavage of the inclusion bodies leading to a 
crude HBD1 solution were monitored by SDS-PAGE (Fig. 3.3). The crude HBD1 
solution was then injected onto a reverse-HPLC system fitted with a semi-preparative 
C18 column. The different eluted fractions were collected and analysed by ESI-MS. 
The fractions including the reduced HBD1 were collected, lyophilized, and reinjected 
onto the C18 semi-preparative column (Fig. 3.4). The main peak at a retention time of 
35-36 min. was analysed by ESI-MS (Fig. 3.4, inset) and a deconvoluted mass of 
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3934.0 ± 2.8 Da was obtained, which is in agreement with the predicted mass of 
3934.6 Da corresponding to the reduced form of the peptide. However, another 
species was present in the sample with a calculated mass of 3982.4 ± 1.55 Da which 
correspond to an increase of 48 Da compared to reduced HBD1. This adducted 
species was difficult to separate from the genuine peptide. Therefore the folding step 
was carried out in the presence of this unknown species.  
 
Figure 3.4. Reverse-phase chromatogram of reduced HBD1. Peak at elution time of 
35-36 minutes was extracted and analysed by ESI-MS. Deconvolution of the +4 
charge state generated masses of 3934 Da and 3982 Da corresponding respectively to 
reduced HBD1 and a 48 Da HBD1 adduct (inset). 
 
 After being subjected to a cysteine/cystine redox buffer for 4 hours, the 
sample was injected onto the semi-preparative C18 column. The main peak eluted at 
33 min. (Fig. 3.5) was manually extracted and analysed by ESI-MS. 
 ESI-MS analysis showed that the main species had a molecular mass of 
3927.5 ± 1.6 Da after deconvolution. This mass approximated the theoretical mass of 
oxidised HBD1 of 3928.6 Da. Unfortunately, the 48 Da adduct previously described 
in the reduced sample was still present with a calculated molecular mass of 3977.2 ± 
0.5 Da corresponding to approximately 5 Da loss compared to the reduced peptide 
mass. This result strongly suggests that the second species is an HBD2 peptide with a 
48 Da adduct. 
[M+4H]+4 
3934 Da (dec.) 
3982 Da (dec.) 
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Figure 3.5. Reverse-phase HPLC chromatogram of HBD2 after a folding step. ESI-
MS analysis of the peak eluted at 33 minutes confirmed the presence of a ~48 Da 
adduct (inset). 
 
 We suggest that the presence of a 48 Da adduct on HBD1 could be due to a 
cysteine oxidation leading to the presence of a cysteic acid. This modification thus 
prohibits disulfide bridge formation between two cysteines. Therefore the peptide 
remains in an incomplete folded state with only the possibility to form two disulfide 
bridges.  
 NMR studies confirmed the lack of folding for HBD1 as the 1D 1H NMR 
spectrum showed a poor dispersion profile noticeable in the amide region at around 8 










Figure 3.6. 1D 1H NMR spectra of HBD1. A poor dispersion profile can be observed 
in the amide region (~8 ppm) suggesting a lack of folding for HBD1. 
3928 Da (dec.) 
3977 Da (dec.) 
[M+4H]+4 
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 Since we encountered technical difficulties with the preparation of HBD1 it 
was decided to focus more on the successful HBD2 studies. Our decision was further 
vindicated by the publication of a tour-de-force study in early 2007 [122]. In this 
report the authors developed a fusion strategy to prepare wild-type HBD1 and 26 
mutants. The authors used a novel trytpophan operon fusion, CNBr cleavage and the 
expensive GSSG/GSG system to oxidise the peptides. The wild type and mutants 
were tested for antimicrobial and chemotactic activity and incredibly, 19 of the 26 
were crystallized. This confirms that a recombinant method is a powerful tool to study 
defensins.  
 
3.3 Conclusions (Chapters 2 & 3) 
 
The isolation and characterisation of various defensins has been a challenge over the 
past 20 years. The process of isolation of such peptides from their natural 
environment yields only a few micrograms of chemically homogeneous product. The 
necessity to develop tools for the production of peptides is required before structural 
and biological analyses can be carried out. In this study we investigated methods for 
production of HBD2 and HBD1. 
 The first method describes the recombinant expression and purification of 
HBD2 in E. coli. The HBD2 gene, codon-optimised for bacterial expression, was 
cloned with a KSI sequence in order to overcome the inherent antimicrobial activity 
of the defensin. KSI acts as an insoluble carrier that inactivates the antimicrobial 
activity of HBD2 during the expression process. The purification process involves 
isolating the inclusion bodies with a series of washes and sonications leading to a 
relatively pure KSI-HBD2 species. These inclusion bodies are solubilised and 
chemically cleaved at a single Met residue using an inexpensive reagent to separate 
the target peptide from the unwanted KSI. Moreover, our method does not use 
expensive proteases which require a specific target cleavage sites which are present in 
the amino acid sequence of the final product. The folding process within the defensin 
field has always been challenging. The disulfide bridge connections are a typical 
signature where defensins fall into 3 sub-families. Six cysteines are always present in 
defensins but their connection varies. The -defensins display disulfide bonds 
between Cys1-Cys5, Cys2-Cys4 and Cys3-Cys6 whereas the -defensins display Cys1-
Cys6, Cys2-Cys4 and Cys3-Cys5 connectivities. After the folding step, HBD2 was 
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purified as a single isoform and proteolysis and MS analysis revealed it to have beta-
defensin connectivity. This peptide was characterised by different biophysical 
techniques (NMR, mass-spectrometry) and its antimicrobial activity tested and 
validated against four strains including Gram-negative strains E. coli and P. 
aeruginosa, Gram-positive S. aureus bacteria and a fungus, C albicans. The HBD2 
was also tested by our collaborator Dr. Julia Dorin against HEK293 cells expressing 
the GPCR receptor CCR6 and was found to be an active chemoattractant peptide (see 
Vargues et al., [128] – Appendix). 
 Furthermore, using surface plasmon resonance, binding studies of HBD2 with 
different membrane models indicated that HBD2 had a higher affinity for negatively-
charged vesicles. However, the higher binding effect was observed when the deep-
rough LPS Kdo2-lipid A was embedded within the membrane. Thus we concluded 
that our method generated HBD2 which was suitable for structural and functional 
studies. 
 In order to carry out defensin/ligand binding studies we investigated the 
expression and purification of the labelled version of HBD2 incorporating the 15N 
isotope. Using the same strategy as previously described, 15N HBD2 was purified with 
an equivalent quality and quantity as observed for the non-labelled HBD2. Mass 
spectrometry and multi-dimensional NMR spectroscopy experiments showed that not 
only the peptide had 100% incorporation of 15N, but the assignment of resonances 
revealed no ambiguous or overlapping peaks. This characteristic was not observed for 
the non-labelled peptide. Therefore the isotopically labelled peptide is a very potent 
tool for studying its interaction with diverse biologically relevant targets from bacteria 
to mammalian immune systems. Our success with HBD2 led us to attempt the 
production of HBD1 by this method, but problems during the purification process led 
to the formation of HBD1 adducts. The HBD1 purification was attempted only once 
and further attempts and optimizations are needed to reach the same standard of 
analytical purity as that found for HBD2. 
 The second method investigated used a chemical approach with solid phase 
peptide synthesis and Fmoc-protected amino acids. This method, allowing the 
chemical synthesis of peptides and small proteins, is very convenient and suitable for 
defensins or antimicrobial peptides as it avoids the fusion-tag strategy to counteract 
their toxicity towards bacteria. Solid-phase peptide synthesis was used to produce 
HBD1. The targeted peptide was 36 amino acids in length and taking into 
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consideration previous published synthetic methods, several attempts to synthesise 
the full length HBD1 remained unsuccessful. A hydrophobic patch of amino acids 
situated in the middle of the sequence made the coupling process difficult leading to a 
mixture of peptide with truncated peptide segments. The recovery and the purity of 
the full length HBD1 were very poor so that the synthesis could not be progressed. 
 The chemical synthesis of HBD2 was also attempted by a colleague with the 
same solid-phase method (E. Seo, data not shown). However, identical problems were 
encountered during the synthesis process and manual coupling was necessary to 
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4.1 Bacteria Fight Back 
 
Over the last 25 years the discovery of hundreds of natural antimicrobial peptides 
found among all classes of life triggered hope that they could be developed into new 
sources of antibiotics and therapeutic agents. Despite the fact that members of the 
“antimicrobial peptide” family display a range of favourable properties with novel 
features, only a select few have proceeded into clinical trials and no published data of 
commercial success have been reported to date [1, 2]. 
 The challenges faced by such compounds in a clinical setting are tightly linked 
to the ingenuous adaptability of pathogenic bacteria presenting multifaceted 
countermeasures to annihilate antibiotic actions. A majority of these countermeasures 
are membrane-related features. In 2003, Yeaman and Yount have published a review 
that summarises the different known mechanisms of bacteria resistance [3]. Within 
the review, the authors present two distinct strategies for resistance, a constitutive (or 
passive) and an inducible (or adaptive) mechanism. Examples of passive resistance 
include electrostatic shielding where bacteria encapsulate in anionic matrices acting as 
a “lure” for cAMPs and also bacteria that constitutively express a membrane pattern 
with more neutral or positively charged components despite the lack of cAMPs in 
their close environment. 
 Some Gram-positive bacteria such as Staphylococcus or Enterococcus species 
“naturally” display structural features within their membrane which render the 
accessibility or interactions of antimicrobial peptides difficult [4]. Membranes of 
Gram-positive bacteria are composed of teichoic acid polymers and peptidoglycans 
and no outer membrane is present in such bacteria. S. aureus display a lipid 
composition enriched in phosphatidyl glycerol (PG) derivatives (modification of PG 
with l-lysine) or teichoic acids (incorporation of d-alanine) substituted with d-alanine 
resulting in a significantly less electronegative membrane composition [5-7]. These 
techoic acids may play a key role in adherence, colonisation, bio-film formation and 
nosocomial infections by Staphylococcus aureus [8, 9]. Moreover, membrane fluidity 
appears to play a key role in S. aureus resistance to platelet microbicidal protein 
(PMP), a small cationic antimicrobial peptide. Bayer and coworkers found a higher 
degree of fluidity in membranes from resistant strains in comparison to PMP-sensitive 
strains [10]. 
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 With regard to the adaptive resistance mechanism, different strategies adopted 
by various microorganisms have been reported. One of the resistance mechanisms 
developed by some bacteria is an efflux-dependent process whereby pathogens are 
able to expel AMPs through energy dependent pumps. Shafer et al. reported this 
mechanism for Neisseria gonorrheoea in 1998 after observing that the susceptibility 
of gonococci towards defensins and various cAMPs was modulated by an energy-
dependent efflux pump termed multiple transferrable resistance (tmr) [11]. Resistance 
involving such efflux systems has also been observed in Yersinia sp., the Gram-
positive bacteria S. aureus and some fungi [12-14]. 
 Another inducible resistance mechanism found in many bacteria is the ability 
to produce proteases or peptidases in response to an antimicrobial stress. In 
Salmonella, an outer membrane endopeptidase (PgtE) was identified and was related 
to the same proteases family found in E. coli and Yersinia [15]. Such proteases are 
able to specifically cleave peptides between two successive basic residues targeting 
various antimicrobial peptides. However, the PgtE protease in Salmonella is unable to 
provide resistance towards antimicrobial peptides with a β-sheet core structure 
constrained by disulfide bridges such as protegrins or defensins. 
 In 2001, a new concept of cAMPs resistance was observed in Shigella species, 
a pathogen able to reduce or turn off the expression of HBD1 and LL37 in infected 
epithelial cells. Despite the lack of molecular evidence, the authors indicated that this 
downregulation could be due to a Shigella plasmid DNA [16]. Various other 
resistance mechanisms which have been reported are either linked to an adaptive or 
innate response. The remarkable adaptability of bacteria generates unlimited 
opportunities to allow them to occupy any kind of niche even under hostile 
environments. In fact many mechanisms, if not ill defined, remain unknown. 
However, it is interesting to draw parallels between antimicrobial peptides and 
resistance mechanism in bacteria as both have evolved side by side in an adaptive or 
innate manner trough a multifaceted creative adversity. 
 Nonetheless, in Gram-negative bacteria, a common and well-studied 
mechanism of resistance is the alteration of their cell envelope by the structural 
modification of a major component of the outer membrane, the lipopolysaccharides 
(LPSs). 
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4.2 LPS and Lipid A Biosynthesis in Gram-Negative Bacteria 
 
LPS is one of the major components of the outer membrane in Gram-negative bacteria 
and belongs to the phosphorylated lipoglycans family. The LPS molecule consists of 
three parts, the O-antigen repeat units, the core polysaccharide and the lipid A (Fig. 
4.1). In a single cell of E. coli, there are approximately 106 lipid A molecules, 107 
glycerophospholipids and 105 undecaprenyl phosphate–sugar residues [17]. Lipid A is 
the hydrophilic anchor of LPS and is also defined as “endotoxin” since it shares the 
structural motif necessary for the activation of the innate immune response via the 
TLR4/CD14/MD2 receptor complex [18-20]. The immune response mechanism 
triggered by LPS is illustrated in an excellent recent review written by Raetz and 
Whitfield [21]. It appears that the lipid A and Kdo (3-deoxy-D-manno-oct-2-ulosonic 
acid) motifs constitute the minimum domain required for Gram-negative bacterial 
growth [17]. However the reasons for such structural domains to be essential for 
bacterial viability and multiplication remain uncertain. 
 In E. coli the core Kdo2-lipid A unit is expressed via a constitutive 
biosynthetic pathway involving nine enzymes each encoded by a single structural 
gene (Fig. 4.2) [22]. These genes are conserved among Gram-negative bacteria with 
the exception of the Sphingomonas species where LPSs are replaced by 
glycosphingolipids [23]. The biosynthetic pathway of Kdo2-lipid A is constitutive in 
all Gram-negative bacteria, and is not dependent on a regulation mechanism, 
supporting the theory that the Kdo2-lipid A core is critical for bacteria growth and 
viability. The early steps of the pathway use water-soluble substrates and LpxA, C 
and D enzymes are cytoplasmic proteins while LpxK, LpxL, KdtA and LpxM are 
inner membrane proteins. Concerning LpxB and LpxH, studies have shown that both 
enzymes were peripheral membrane proteins [22]. Interestingly, due to the central 
position of such enzymes in the bacteria viability and growth, they appear to be ideal 
drug targets. Recently, McClerren and colleagues have reported a LpxC inhibitor 
termed CHIR-090 that was tested against diverse strains including E. coli and P. 



































Figure 4.1. From Gram-negative bacteria cell wall to LPS. Model of the outer and 
inner membrane in E. coli K12 strain with the structure of Kdo2-lipid A. Adapted 
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
Figure 4.2. Structure and biosynthesis of Kdo2-lipid A in E. coli K-12 strain. The 
figure was taken from Raetz et al., 2007 [22]. 

 The newly synthesised Kdo2-lipid A is flipped from the inner side to the outer 
surface of the inner membrane by an ABC transporter MsbA. The msbA gene was first 
reported as essential for E. coli viability in 1993 by Karow and Georgopoulos [27]. A 
few years later it was proposed that the MsbA protein could be the inner membrane 
flippase for the core lipid A and could be the quality filter element for the LPS 
transport system [28]. The full mechanism of export of LPS from the inner membrane 
to the exterior of the outer membrane still remains unclear. The transport process of a 
hydrophobic molecule through an hydrophilic milieu, the periplasm, is 
thermodynamically unfavorable and until recently, little was known about such 
physiological mechanisms. However in a recent review, and in light of new studies, 
Sperandeo and colleagues have proposed new insights concerning such a puzzling 
matter [29]. A cluster of three genes essential for E. coli viability was identified and 
the genes termed lptA, lptB and lptC [30, 31]. The authors demonstrated that the 
lipopolysaccharide transport (Lpt) machinery including proteins LptA, B, C, D, E, F 
and G was operating downstream of MsbA, which resulted in the formation of a large 
complex that could span the periplasmic region (Fig. 4.3). LptA was shown to bind 
Chapter 4: Into the Resistance 
72 
lipid A and shield its hydrophobic region facilitating its passage trough a soluble 
milieu. Moreover LptA binds indiscriminately hexa or tetraacylated lipid A, which 
suggests that the LPS filter selection might occur upstream the Lpt machinery and 
could be carried out by MsbA [32]. Very recently the structure of ligan-free E. coli 
LptA revealed a highly-unusual fold and the protein displayed oligomeric properties 











Figure 4.3. Model for the LPS transport through the periplasm in Gram-negative 
bacteria according to Sperandeo and coworkers, 2009 [29]. 
 
4.3 Lipid A Modifications in Gram-Negative Bacteria  
 
The ability of Gram-negative bacteria to resist and adapt to environmental stress 
partly resides in their aptitude to induce covalent modifications on the lipid A core 
moiety of LPS. In contrast to the biosynthetic pathway of lipid A, which is 
constitutively expressed, the lipid A modification mechanism is an induced 
phenomenon mediated by various conditions such as the presence of divalent cation 
concentrations, AMPs or changes in pH. For instance, low concentration of Mg2+, 
high concentrations of Fe3+ or acidic pH have been reported to trigger bacterial 
resistance via lipid A modifications, but millimolar concentrations of magnesium or 
calcium downregulate the effect [34, 35]. In E. coli, S. typhimurium and the majority 
of Gram-negative bacteria, these modifications are under the regulation of the two-
component systems (TCSs) PhoP-PhoQ and PmrA-PmrB [36-38]. 
 PhoQ protein was reported to be activated directly by AMPs [39]. When 
AMPs bind to the phosphate group of lipid A, they displace divalent cations and 
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therefore activate PhoQ which according to Bader et al. acts as an antimicrobial 
sensor. The PmrA/B TCS was first described in 1993 and named after the study of a 
mutated strain resistant to Polymyxin B (PMB), a small cationic antimicrobial 
peptide, and other AMPs [40, 41]. PMB is a natural compound produced by Bacillus 
polymyxa [42]. Both PMB and its synthetic derivative colistinhave been extensively 
used and tested towards various bacteria however, it appears that they have little 
effect towards Gram-positive microorganisms. The PMB peptide is used as a 
reference for clinical and in-vitro killing tests for Gram-negative bacteria. PMB has 
been used as an antibiotic reference and S. typhimurium as the bacterial model for the 
study of the two-component systems in relation with bacteria virulence. So far, thirty 
eight TCSs have been identified in this species [43]. 
 PmrA/B can be initiated by PhoP/Q TCS but it can also independently induce 
modifications [38]. Such modifications appear to be one of the primary roles of 
PmrA/B and include the covalent addition of groups on both LPS and lipid A core. 
For example, two modifications consist with the attachment of phosphoetanolamine 
(pEtN) and aminoarabinose (4-amino-4deoxy-L-arabinose, L-Ara4N, discussed later 
c. f. part 4.5) by respectively EptA and ArnT enzymes on the different phosphate 
group of the lipid A moiety [44, 45].  
 These modifications not only mask the negative charges of the phosphate 
groups but also add a positive moiety to the lipid A core as both pEtN and L-Ara4N 
are cationic at neutral pH. 
 In Salmonella and E. coli bacteria, the transfer of phosphoethanolamine by 
EptA occurs on the outer side of the inner membrane and essentially at position 1 of 
phosphate group (Fig. 4.4) [46]. However with the absence of L-Ara4N modifications 
and under specific growth conditions, a second pEtN can be attached to the 4’ position 
of the lipid A [47]. Additionally, pEtN can be incorporated to the first heptose of the 
LPS core by the product of the cptA gene [48]. In E. coli-K12 strain, the transfer of 
phosphoethanolamine only occurs under mild acidic condition whereas it is 
constitutively expressed in the pathogenic E. coli O157:H7 suggesting a relation 
between virulence and pEtN modifications [49]. Phosphoethanolamine moiety can be 
also incorporated by EptB, a homologous protein to EptA in S. typhimurium and E. 
coli. In contrast to EptA, EptB is not under the control of PmrA but is regulated by the 

E transcription factor and the transfer of pEtN by EptB is carried out on the outer 
Kdo sugar of lipid A (Fig. 4.4) [50]. 




Figure 4.4. Covalent modifications of Kdo2-lipid A in E. coli K-12 and Salmonella. 
The blue numbers represent the glucosamine ring positions. Adapted from Raetz et 
al., 2007 [22]. 
 
 In Neisseria meningitidis, a bacterium unable to incorporate L-Ara4N, it was 
found that pEtN modifications are present and directly-related to the PMB resistance 
for this human pathogen [51]. But contrary to L-Ara4N modifications, which are 
decisive for PMB resistance [52, 53], the functions of pEtN modifications remain 
unclear. Other modifications of lipid A have been reported and involve the fatty acyl 
chain moiety. The incorporation of the fatty acid palmitate in E. coli and S. 
typhimurium is carried out by the PagP protein (Fig. 4.4) and controlled by the 
PhoP/PhoQ system itself activated by cAMPs or low Mg2+ concentration  [47, 54]. 
PagP is an outer membrane enzyme which uses phospholipids as palmitoyl donors 
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[55]. The reaction of palmitoylation occurs in the outer side of the outer membrane 
and this process could be modulated by the accessibility of phosphate sporadically 
present on this side of the membrane [56]. S. typhimurium mutants lacking the 
palmitate moiety on the lipid A were shown to be sensitive to cationic AMPs. 
Membrane permeabilisation was shown to be faster than wild type strains when 
exposed to different structural classes of cAMPs such as C18G and protegrin peptides 
[57]. Moreover, the pagP gene seems to be highly related to the virulence of bacteria 
and regulated in close relation to their pathogenic ability. Hence PagP expression 
appears to be the privilege of only a certain class of pathogenic bacteria [58].  
 Additional enzymes found in Salmonella but not in the E. coli K-12 wild-type 
strain have been reported to modify lipid A. LpxR, an outer membrane lipase can 
remove the 3’-O-acyloxyacyl residue of lipid A under high concentration of Ca2+ and 
the presence of Kdo moiety [59]. PagL is also an outer membrane esterase that 
catalyses the 3-O-deacylation of lipid A at position 3 [60]. If both outer membrane 
enzymes are regulated by PhoP/PhoQ system it is not the case for LpxO, an inner 
membrane protein which uses -ketoglutarate, Fe3+ and oxygen cofactors to 
hydroxylate the secondary acyl chain at 3’ position of lipid A [61, 62]. The roles of 
these three enzymes are unclear but it seems that LpxR and PagL could reduce the 
cytokine activation effect of LPS [63, 64]. All modifications mentioned above are 
represented on figure 4.4. 
 It appears that lipid A modifications are “mandatory” for pathogenic bacteria. 
In fact, LPSs constitute not only a “shield” acting as a defense barrier but its flexible 
architecture elaborated by various modifications can also dictate a level of bacterial 
virulence. Therefore, it is interesting to note that the capacity of resistance and 
adaptation of a microorganism often¸ if not always correlates somehow with its 
degree of pathogenicity.  
 Aminoarabinose modifications on lipid A have been directly related with a 
resistance mechanism towards all sort of antibiotics. Such modifications are induced 
by diverse stimuli in most Gram-negative bacteria and are under the control of 
regulators such as PhoP/Q and PmrA/B systems. However some bacteria have 
evolved to protect themselves and therefore have enhanced their virulence. This is the 
case of bacterial species found in the Burkholderia cepacia complex (Bcc) where 
bacteria are able to constitutively express aminoarabinose modifications on the lipid A 
core [65]. This characteristic is crucial for antibiotic resistance towards PMB. In  
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2003, Shimomura et al. have observed an unusual interaction between LPS from B. 
cepacia and PMB. LPSs not only bound to PMB with high affinity, in spite of 
containing Ara4N, but also increased its IL-1ß-inducing activity [66]. The authors 
have concluded that LPS from B. cepacia has unique characteristics in both structure 
and activity. Interestingly, highly pathogenic and resistant bacteria from Bcc can be 
found in the lung environment of cystic fibrosis (CF) sufferers and 
immunocompromised patients [67a]. Constitutive modifications of Lipid A by the 
aminoarabinose moiety in such bacteria may play a crucial role in the invasion and 
deterioration of cystic fibrosis patients’ lung tracts [67b]. 
 
4.4 Cystic Fibrosis (CF) and The Burkholderia Cepacia Complex  
 
Cystic fibrosis is a monogenic autosomal recessive disease and is also the most 
common life-threatening disease among people of European heritage. In UK, 8000 
individuals are diagnosed with CF (www.cftrust.org.uk) and 1 out of 25 people carries 
the defective gene. The average life expectancy for CF patients lays netween 30 to 40 
years. This genetic disorder, when expressed, affects various organs such as the liver, 
the pancreas but also tissues in the respiratory, gastrointestinal and reproductive tracts. 
CF is caused by mutations located on the cystic fibrosis transmembrane conductance 
regulator gene (CFTR). The gene encodes a member of the ATP-binding cassette 
(ABC) transporter family; the CFTR protein with a molecular weight of 168 kDa [68, 
69]. This protein is located in the epithelia cells of skin and all tracts mentioned 
above. The protein acts as an anion channel regulator that mediates anion 
conductance, a crucial function for the maintenance of ion equilibrium and fluid 
homeostasis in epithelia cells [70]. First reported as a chloride channel, CFTR can 
also inhibit sodium absorption in lung epithelial cells and play an important role in 
HCO3
- secretion [68, 71]. 
Over 1600 mutations have been identified on the CFTR gene 
(www.genet.sickkids.on.ca/cftr/StatisticsPage.html). These mutations have been 
classified into 6 classes (I to VI) according to the protein domain affected and their 
nature; frame shift, nonsense or splice site mutations [72, 73]. Not all mutation lead 
systematically to CF but the most common mutation, a 3-bp deletion termed F508, 
accounts for 70% of worldwide cystic fibrosis cases 
(www.ornl.gov/sci/techresources/Human_Genome/posters/chromosome/cftr.shtml). 
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This class II deletion results in the loss of only a phenylalanine at position 508 of the 
CFTR protein but has dramatic effects for the F508 homozygous individuals [74]. 
F508 mutation creates an abnormal fold which prevents the protein to be matured 
properly leading to its degradation by the cell [75].  
Consequently, loss of CFTR-associated functions leads to impaired pancreatic 
HCO3
- and chloride secretion, enhanced Na+ absorption, dehydration of the airway 
surface which impairs mucociliarity clearance [76]. Such physiological alterations 
contribute to immunodeficiency in lung environment and are propitious for chronic 
airway invasion by opportunistic pathogens. Lung disease represents the major cause 
of morbidity and mortality in CF community. Examples of pathogenic bacteria 
species found in airways of CF patients include S. aureus, P. aeruginosa and B. 
cepacia. The latter was reported to be the most contagious and problematic among 
pathogens leading to drastic changes in clinical and social habits for CF patients [77]. 
 Half a century ago, a plant pathogen that causes onion bulb rot was identified 
by Walker H. Burkholder [78]. Despite being an emerging concern among cystic 
fibrosis and immunocompromised patients over the past two decades [79 Goldmann, 
80], Bcc species are ecologically versatile Gram-negative bacteria found in water, soil 
and rhizosphere of plants [81]. They are able to protect plants from disease and 
degrade environmental pollutants. Such abilities have been attributed to their 
remarkable genomic complexity [82]. In fact, Bcc bacteria possess some of the largest 
genomes ever observed within Gram-negative species (6 to 9 Mb) and are usually 
shared by two or three chromosomes. Previously reported as Pseudomonas cepacia 
due to their phenotypic resemblance with the Pseudomonas genus, Bcc bacteria were 
transferred to the Burkholderia genus in 1992 [83]. This differentiation was followed 
in 1997 by a new classification within the B. cepacia genus where five sub groups 
were organised into genomovars [84]. With the recent addition of 6 new species [85], 
a total of fifteen genomovars (I to XV) have been identified to date [86].  
 Among the Burkholderia cepacia complex, two species have been highly 
related to CF disease; B. multivorans and B. cenocepacia (Genomovar II and III). If 
both strains are responsible for epidemic outbreaks and are transmissible between 
patients, B. cenocepacia represent the major issue for CF infection with 70% rate of 
Bcc infection [87, 88]. Moreover, B. cenocepacia has the remarkable ability to 
overtake B. multivorans during CF infection [89]. Over the past two decades, 
increasing concern and effort have been focused on three epidemic strains in B. 
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cenocepacia; the Midwest, PHDC and ET-12 lineages. These strains are responsible 
for the main morbidity and mortality in the cystic fibrosis community with the latter 
being the cause of the largest CF epidemic in the late 80’s to mid 90’s spreading 
through Canada, United Kingdom and Europe [90, 91].  
 B. cenocepacia J2315 strain is a member of the epidemic ET-12 lineage. It 
was isolated by Prof. Govan and colleagues in 1989 during an epidemic outbreak 
amongst Scottish CF sufferers. It is a highly resistant microorganism against all class 
of antibiotics and was recently sequenced [92]. The genome of the J2315 strain is 
organised in three large chromosomal replicons and a small plasmid for a total size of 
approximately 8 Mb. The gene cluster responsible for aminoarabinose modification 
on lipid A is located on chromosome 1. The sequence of J2315 genome is available at 
www.sanger.ac.uk/Projects/B_cenocepacia/. 
 
4.5 The Biosynthetic Pathway of Aminoarabinose (L-Ara4N) Modification 
of Lipid A: The Burkholderia Cenocepacia Case 
 
The mechanism of L-Ara4N modification of lipid A was first described and mainly 
studied in E. coli and S. typhimurium (Fig. 4.5). All genes involved in this pathway 
with the exception of ugd (the gene encoding for the first enzyme) are located in the 
arn operon which is divided in two transcription units; arnBCAD and arnTFE (Fig. 
4.5 B) [52, 93]. Originally termed the pmr operon due to its relation to PMB 




































Figure 4.5. A. Biosynthetic pathway of aminoarabinose (L-Ara4N, blue) and its 
attachement to Lipid A moiety (A). B. Organisation of the arn operon from B. 
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 Eight proteins are involved in the biosynthetic pathway of L-Ara4N 
modification in E. coli and S. typhimurium (Fig. 4.5 A, in blue characters) [22]. The 
first step is carried out by an UDP-glucose dehydrogenase (UgD) that converts UDP-
glucose to UDP-glucuronic acid [52]. The second step is the oxidative 
decarboxylation of UgD product to release UDP-4’’-ketopentose (UDP-Ara4O). This 
reaction is carried out by the C-terminal domain of ArnA [94]. Newly synthesised 
ketosugar is then transaminated by a PLP-dependent enzyme, ArnB, which uses 
glutamate as cofactor [95]. In vitro studies of the transamination reaction for the 
production of aminoarabinose is unfavorable. It suggests that the following enzyme, 
ArnA, shifts the equilibrium to the formation of L-Ara4N. Indeed, the biosynthesis of 
UDP-L-Ara4-formyl-N by the N-terminal domain of ArnA would compensate for the 
unfavorable formation of UDP-L-Ara4-FN. However, despite the fact that X-ray 
structures of both ArnA and ArnB have been solved, the interaction and transfer of 
product and substrates between their active site is unknown [94-97]. ArnC, the third 
enzyme of the pathway, is extremely specific and accepts only the N-formyl substrate 
and then transfers L-Ara4-FN onto an undecaprenyl phosphate moiety [94]. 
Deformylation by ArnD to undecaprenyl phosphate Ara4N is necessary for its 
transport trough the inner membrane protein [94]. Recently Yan and coworkers have 
reported that an undecaprenyl phosphate L-Ara4N flippase was necessary for the 
PMB resistance in E. coli [98]. ArnE and ArnF, two inner membrane proteins, would 
likely form an homodimer to flip out the ArnD product to the periplasmic side of the 
inner membrane. Finally, an additional inner membrane protein, ArnT, incorporate L-
Ara4N to the 4’-phosphate group of lipid A moiety [44]. 
 Recently, homologues of the arn genes were found in B. cenocepacia J2315 
[99]. The authors demonstrated that this operon was essential for B. cenocepacia K56-
2 viability (K56-2 strain is clonally related to J2315 strain and was used since it is 
amenable to genetic manipulation). However it shares a different genetic organisation 
than its homologues previously described in E. coli and Salmonella. The arn operon 
in B. cenocepacia is transcribed as follows: arnTG/arnBCA1A2D (Fig. 4.5 B). Ortega 
et al. have used conditional mutants where a rhamnose-inducible promoter was 
inserted upstream of arnB (XAO12) and arnT (XAO11) genes. When the promoter 
was “switched-off” by the addition of glucose, it highly affected the viability of the 
cells and deformation of the cell envelope was observed (Fig. 4.6, XOA11 and 
XOA12) [99]. Although the authors did not determine if the membraneous material 
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was modified by Ara4N it still provided a link between the arn operon and some 
essential process for the viability of B. cenocepacia. However, the exact reason for the 
requirement of this locus by such bacteria is still not clear. 
 
        
Figure 4.6. Ultrastructural analysis of bacterial cells of K56-2, XOA11 and XOA12 
strains by transmission electron microscopy. This figure was taken from Ortega et al., 
2007 [99]. 
 
 Concerning B. cenocepacia and more generally Burkholderia species, the 
biosynthetic pathway of L-Ara4N modifications on lipid A is constitutively expressed. 
This is in contrast to other microbes where this process appears to be an adaptive 
“option”. This exceptional ability allows this species to be highly advanced in terms 
of resistance and virulence.  
 Although in silico analysis suggest similar characteristics in the L-Ara4N 
modification pathway, the genomic organisation of arn operon from B. cenocepacia 
possesses two obvious differences from non Bcc specie and it concerns arnA and 
arnG genes (Fig. 4.5 B). In E. coli and S. typhimurium, one gene encodes for ArnA 
protein that contains two catalytic domains (N- and C-termini), which are able to 
proceed two enzymatic reactions. In contrast, B. cenocepacia shares two genes, arnA1 
and arnA2, encoding for two distinct proteins: ArnA1 and ArnA2 [99]. Both enzymes 
carry out the same reactions that ArnA does in E. coli and Salmonella. Concerning the 
arnG gene, an opposite phenomenom takes place, ArnE and ArnF proteins have been 
reported to associate as an heterodimer for the flippase activity in E. coli while one 
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protein acting hypothetically as an homodimer (ArnG) could complete the same 
reaction in B. cenocepacia. 
 So far only few biochemical studies have been carried out on the different 
enzymes responsible of L-Ara4N modification in B. cenocepacia. Recently, the Ugd 
homologs that encode UDP-glucose dehydrogenase, the first enzyme of the pathway 
were characterized by our groups in collaboration with Miguel Valvano. The authors 
identified 3 ugd genes in the genome, but only two were essential for B. cenocepacia 
viability and one was required for PMB resistance [100]. 
 
4.6 Structure of B. Cenocepacia Lipopolysaccharide 
 
 In Bcc, many virulence factors are thought to be responsible for the clinical 
outcomes. Examples of such factors include zinc metalloproteases [101], siderophores 
[102], haemolysins [103], flagella [104], exopolysaccharides (EPSs) [105] or adhesins 
[106]. However, one of the major virulence factors of B. cenocepacia and most Gram-
negative bacteria, is the LPS molecule which is a potent inflammatory agent [107]. 
LPSs from the Bcc group, have been shown to be more endotoxic and ninefold more 
efficient to release cytokines from leukocytes than LPSs found in Pseudomonas 
aeruginosa [108 Shaw]. Until recently, little was known about the LPS structure in 
Burkholderia cenocepacia. 
 In 2007, a structure of rough LPS (lipooligosaccharide, LOS) from B. 
cenocepacia J2315 strain was published by Silipo et al. [109]. The Ara4N-Ko(D-
glycero-D-talo-octulosonic acid)-Kdo(3-deoxy-D-manno-octulosonic acid) unique 
feature shared by Burkholderia species reported by others was confirmed by structural 
methods such as NMR and mass spectrometry (Fig. 4.7 A) [110, 65]. This 
trisaccharide moiety is distinct from E. coli and Salmonella (Kdo2) and the presence 
of Ko monosaccharide is shared by only few bacteria specie such as Serratia, 
Acinetobacter and Yersinia [111-113]. In addition to the Ara4N-Ko-Kdo moiety, the 
core oligosaccharide (OS) is constituted of 3 heptoses in the inner core region and two 
glucose sugars are attached to heptose I and heptose II which carries also a terminal 
heptose (Fig. 4.7 B). Recently, it was demonstrated that the core level truncations of 
LOS derived from smooth LPS K56-2 strains was proportionally linked to the level of 
PMB resistance [114]. Moreover, the heptose-less mutant was not able to survive in 
macrophages contrary to the wild-type strain. 
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 LPSs extracted from Burkholderia J2315 strain consisted of a mixture of tetra- 
and pentaacylated lipid A species [109]. The main species, a tetraacylated lipid A, 
carried two 14:0 chains and two 16:0 chains with a secondary fatty acid attached to 
one of the 16:0 chain (Fig. 4.7 A). The presence of this secondary acylation in lipid A 
could be crucial for the induction of inflammatory responses and the integrity of the 



























Figure 4.7. Structure (A) and sugar organisation (B) of the lipooligosaccharide from 
Burkholderia cenocepacia (J2315 strain). The dotted line indicates non-stoichiometric 



















Due to the essential role of the L-Ara4N biosynthetic pathway for B. cenocepacia 
viability (Ortega et al., 2007 [99]), it was felt that we should explore the potential of 
inhibiting this pathway as a way of weakening these pathogens. The goal of this part 
was to investigate the biochemical characteristics of two proteins involved in the 
biosynthesis of aminoarabinose in B. cenocepacia J2315. The first enzyme studied, 
the aminotransferase ArnB, was previously purified from S. typhimurium and E. coli 
and was identified as a cytoplasmic, PLP-dependent enzyme. In vitro studies have 
shown that the natural-product antibiotic cycloserine, could inhibit ArnB irreversibly. 
 Our second target was the putative B. cenocepacia undecaprenyl phosphate 
Ara4N flippase ArnG. This protein shows low sequence homology but high amino 
acids topology to two recently characterised E. coli inner-membrane proteins ArnE 
and ArnF. Both proteins have been reported to be necessary for the flippase activity in 
E. coli [98]. 
 Recently, a study was undertaken to evaluate the antibacterial activity of eight 
cAMPs towards strains from the Burkholderia cepacia complex [117]. Of all the 
cAMPs used, only magainin II was reported to display a “moderate” activity against 
the different Bcc strains. This example highlights the difficult challenge remaining to 
eradicate bacterial infection caused by these organisms. New drugs and/or the 
combination of a mixture of antibiotics may decrease the resistance and virulence of 
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biosynthesis in Burkholderia cenocepacia. 
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5.1 Analysis of the arn Operon in B. cenocepacia J2315 
 
The arn gene cluster (arnTG/arnBCA1A2D) is responsible for aminoarabinose 
biosynthesis and its attachment to lipid A in Burkholderia cenocepacia. The arn 
operon is present in a region spanning nucleotides 2128443 to 2135736 in 
chromosome 1 of B. cenocepacia strain J2315 
(www.sanger.ac.uk/Projects/B_cenocepacia/). The sequence corresponding to this 
operon (and of the total genome, [91]) enabled us to design primers to clone the genes 
encoding the Arn enzymes from B. cenocepacia. Analysis of the J2315 strain suggests 
it has 7261 coding sequences, a large number for a Gram negative organism. The 
genes have been annotated with BCAL numbers. 
 Concerning the ArnB protein, previous studies from E. coli and S. 
typhimurium have shown that the protein (encoded by pmrH, BCAL 1931) is a 
pyridoxal 5’-phosphate (PLP)-dependent aminotransferase enzyme [95]. It catalyses 
the reversible transfer of the -amine moiety from an amino acid donor (L-glutamate) 
to the C-4 position of UDP-Ara4O, generating UDP-L-Ara4N (Discussed later in this 
section). The reaction occurs via an enzyme-pyridoxamine 5’-phosphate (PMP) form. 
Sequence alignment of ArnB from B. cenocepacia with orthologs from E. coli K12, S. 
typhimurium and P. aeruginosa (PAO1) revealed similarities in sequences (Fig.5.1). 
Homology scores between the ArnB from B. cenocepacia and the three strains lie 
between 50% and 52%. 
 Structural studies of the ArnB from S. typhimurium revealed it to be a 
homodimer where the PLP cofactor is bound to the enzyme via a lysine residue, 
forming an internal aldimine [95]. This lysine residue is conserved through various 
bacteria species and is present at position 188 in the S. typhimurium homolog (Fig. 
5.1). It could act as a catalytic acid/base entity involved in several steps of the enzyme 
reaction (Fig. 5.2 B). Moreover, two residues have been identified to be the selective 
filter for the amine donor, Lys241 and Arg229. If the Lys241 residue is also present in 
the alignment study for the B. cenocepacia strain the arginine 229 residue is missing 
(Fig 5.1). However, another arginine residue present at position 218 could be the 



































Figure 5.1 Sequence alignment of ArnB from E. coli, P. aeruginosa, S typhimurium 
and B. cenocepacia J2315. In blue are highlighted the residues involved in the 
selective filter for the amino donor substrate. Red circles represent some residues 
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 The full reaction mechanism of ArnB is described in figure 5.2 and is directly 
adapted from the study mentioned above [95]. 
 The first part of the reaction (Fig. 5.2 A) include the following steps: 
formation of an external aldimine via displacement of the lysine-PLP internal 
aldimine (holo-ArnB) by the incoming amino-acid substrate (L-glutamate); formation 
of a quinonoid intermediate by abstraction of the -proton from the PLP-amino acid 
external aldimine; reprotonation of the quinonoid to form the ketimine 1 intermediate 
which hydrolysed to form the first product -ketoglutarate and the reduced cofactor 
form PMP. 
 In the second part (Fig. 5.2 C), the UDP-LAra4O substrate reacts with PMP to 
form the ketimine 2 intermediate by abstraction of the -proton; reprotonation of 
quinonoid 2 to form the external aldimine 2 intermediate; and finally release of the 













































































































































































































Figure 5.2. General (A) and detailed (B and C) mechanisms of transamination from 
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 The ArnG protein form B. cenocepacia (encoded by BCAL 1930) possesses a 
unique feature as it is encoded by one gene whereas the E. coli ortholog is encoded by 
two genes, arnE and arnF (previously termed pmrL and pmrM respectively). The 
arnT and arnE/F genes are located downstream of the arnBCAD genes in E. coli. In 
contrast, the arnT and arnG genes are situated upstream of the same genes in the B. 
cenocepacia arn operon. In E. coli, both ArnE and ArnF proteins have been shown to 
be indispensable for the flippase activity of undecaprenyl phosphate-aminoarabinose 
[98]. 
 Despite low homology and sequence identity when comparing ArnG with 
ArnE and ArnF (22.1% and 27.4 % identity respectively), the amino acid 
characteristics are highly similar (Fig. 5.3). Topology prediction was also performed 
for ArnG in this study using the hidden Markov model topology predictor software 




Figure 5.3 Amino acid topology of ArnE, ArnF and ArnG. The profile of charged, 
acidic, basic, polar and hydrophobic amino acids is very similar.  
 
 Figure 5.4 indicates that the protein could share a 4 transmembrane helical 
domain with both N and C-termini present in the cytoplasmic side of the membrane. 
 
ArnG (123)   
Amino Acid(s)  Number count   % by weight   % by frequency  
Charged (RKHYCDE) 17    17.50    13.82  
Acidic (DE)   3    2.81    2.44  
Basic (KR)   6    6.51    4.88  
Polar (NCQSTY)  25    21.49    20.33  
Hydrophobic (AILFWV)  68    55.78    55.28  
 
ArnE (128)  
Amino Acid(s)  Number count   % by weight   % by frequency 
Charged (RKHYCDE) 20    18.97    15.63  
Acidic (DE)  3    2.52    2.34  
Basic (KR)  7    6.59    5.47  
Polar (NCQSTY) 25    19.49    19.53  
Hydrophobic (AILFWV) 69    54.77    53.91 
ArnF (111) 
Amino Acid(s)  Number count   % by weight   % by frequency 
Charged (RKHYCDE) 16    16.83    14.41  
Acidic (DE)  1    1.04    0.90  
Basic (KR)  7    7.81    6.31  
Polar (NCQSTY) 21    18.69    18.92  
Hydrophobic (AILFWV) 64    58.53    57.66  
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Predicted topology study for ArnE and ArnF also suggested that both proteins could 
share a 4 transmembrane helical domain and act as a heterodimer (Fig. 5.5 A) [98]. 
Hence we speculated that ArnG could also be active as a homodimer (Fig. 5.5 B). 
 Bioinformatic studies such as topology predictor software are informative 
tools allowing quick access to sets of data including the quantitative capability of a 
protein to be embedded in a membrane and the possible location of its N- and C- 
termini. However, the certainty of such approach remains improbable and despite 





















Figure 5.5 Proposed topography of the ArnE/ArnF heterodimer (A) [98] and ArnG 
homodimer (B). 
 
Both proteins present interesting aspects. To start with, enzymes involved in 
the pathway of lipid A modification with aminoarabinose in B. cenocepacia appear to 
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that confers antibiotic resistance to such pathogenic bacteria but is also crucial for 
their viability. It is therefore interesting to exploit this paradox as it seems to be the 
Achille’s heel of this bacterium.  
 ArnB, a PLP-dependent enzyme, can be tested with various inhibitors in vitro 
and in vivo in order to create a breach in the B. cenocepacia shield. ArnG, could be 
another key protein in the resistance mechanism in such bacteria. ArnG presents 
striking similarities with ArnE/F, two proteins which action is crucial for E. coli 
resistance against antibiotics. The inner membrane flippase activity demonstrated for 
ArnE/F could also be confirmed for ArnG in B. cenocepacia. Interestingly, ArnG 
sequence is unique to Burkholderia species as no homolog was found in other 
bacteria. 
 
5.2 Cloning, Expression and Purification of ArnB from B. cenocepacia 
 
The purification of ArnB from S. typhimurium for structural studies was carried out 
with a C-terminal hexa-histidine tag [95]. We decided to adopt the same strategy by 
including a histidine tag at the C-terminal end of the arnB sequence. 
 The gene was amplified by PCR using genomic DNA from B. cenocepacia 
J2315 as a template and ligated into pGEM-T Easy vector. DNA sequencing 
confirmed the exact gene sequence according to the published genome. Subsequently 
arnB gene was cloned into the pET22b vector (Novagen) where an extra 
LAAALEHHHHHH fusion tag sequence was added at the C-terminus resulting in 
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 After transformation of BL21(DE3) competent cells with pET22b-ArnB, 
bacterial cells were grown at 37 ºC in shake flasks and induced with 0.5 mM 
isopropyl-1-thio-β-D-galactopyranoside (IPTG) for 5 hours. These cells were then 
used as a source of soluble ArnB. Samples from each main step of purification were 
analysed by SDS-PAGE (Fig. 5.7). 
 Lane 1 and 2 in the gel represent respectively the cell-free extract before and 
after induction with IPTG. A band at around 43 kDa is revealed after induction 
corresponding to the theoretical mass of ArnB. After sonication, residual insoluble 












Figure 5.7 SDS-PAGE 12% gel showing the main steps of ArnB expression and 
purification; 1 and 2, cells before and after induction; 3, cell extract washed with 20 
mM imidazole buffer; 4, protein elution with 100 mM imidazole buffer; 5, protein 
purification profile after SEC. 
 
 The soluble fraction was first purified by immobilised metal-affinity 
chromatography (IMAC) with a nickel resin. The ArnB cell lysate was poured onto a 
nickel resin column and washed with the binding buffer containing 20 mM imidazole 
(Fig. 5.7 lane 3). The protein was then eluted with 100 mM imidazole. The eluted 
ArnB protein is shown in band 4 with a thick distinct band at 43 kDa, but despite a 
dramatic increase in the sample purity, contaminants were still present at this stage. A 
second purification step was introduced with a size exclusion column (SEC) 
chromatography. 
 The protein was then loaded onto a Sephacryl High Resolution Column S200 
for a higher level of purification. ArnB protein was eluted from the column and 
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fractions 12, 13 and 14 (Fig. 5.8) were pooled together and analysed by SDS-PAGE 
(Fig. 5.7, band 5). A well defined band at 43 kDa with no visible contaminants was 
obtained with purity greater than 95 % according to the gel profile. The elution profile 
of ArnB indicated that the protein was purified as a homodimer according to the 
calibration curve calculated from standard samples for this column (see Chapter 6, 
section 6.2.4.5). 
 The concentration of the purified ArnB protein was measured with the BCATM 
assay and the final quantity of ArnB purified from 3 litres of E. coli cells was 
calculated to be ~25 mg. ArnB samples were eventually aliquoted in buffer containing 














Figure 5.8. Sephacryl S200 High Resolution Column chromatograph of ArnB. In inlet 
is represented the SDS-PAGE gel profile of fractions 12 to 14. 
 
 A sample of freshly purified ArnB enzyme was analysed by high resolution 
FT-ICR MS. The mass spectrum (Fig. 5.9), shows an ion envelope and the calculated 
mass from the deconvoluted spectrum was 43,121 Da corresponding to a difference of 
131 Da from the theoretical mass (43,252 Da) suggesting the loss of the starting 
amino acid methionine. The loss of the N-terminal methionine residue is a common 
phenomenon in the E. coli expression system.  
 
 























Figure 5.9. High resolution FT-ICR Mass Spectrometry of ArnB. 
 
5.3 Spectroscopic Characterisation of ArnB 
 
Prior to any further manipulation, the enzyme was dialysed overnight with an excess 
of fresh PLP followed by removal of unbound cofactor with a PD10 column. 
 The reaction catalysed by the ArnB aminotransferase is summarised in figure 
5.2. The reaction consists of two main steps. In the first step, the complex enzyme-
PLP is converted to enzyme-PMP form by activation with the amino donor. In the 
second step, the substrate, UDP-4’-ketopentose binds to the active site where the 
amine group is transferred to produce UDP-L-Ara4N. Here, we focused our attention 
on the reaction between of the co-substrate and ArnB-PLP. This reaction is called 
“half reaction” in the following. Freshly prepared ArnB was first characterised in its 
holo-form by UV-visible spectroscopy at a concentration of 10 µM (Fig. 5.10). The 
reaction was monitored by UV-visible spectrophotometry. A typical profile of PLP-
dependent enzymes is shown on the spectrum as ArnB-PLP presents two 
characteristic peaks at 420 nm and 330 nm (Fig. 5.10). These two absorbances are the 
result of an equilibrium between tautomers of the external aldimine species; the 
ketoenamine and the enolimine forms. 
 
 






































Theoretical mass: 43252 Da 
 
Experimental mass: 43121 Da 




















Figure 5.10 UV-visible spectrum of freshly purified ArnB (10 µM) in its holo-form 
(ArnB-PLP).  
 
 The first amino acid tested as the amine donor was the l-glutamate as it has 
previously been shown that it could be the physiological co-substrate for ArnB in E. 
coli and S. typhimurium. Increasing concentrations of l-glutamate (1 µM - 100 µM) 
was added to the enzyme ArnB-PLP and changes monitored by UV-visible 
spectrophotometry. The absorbance previously described and recorded at 420 nm for 
the holo-form decreases with the increasing amounts of l-glutamate while the signal 
intensity at 330 nm increases (Fig. 5.11). The peak at 330 nm represents the maximum 
of absorbance for the E-PMP species whereas ArnB E-PLP form possesses its 
maximum absorbance at 420 nm. The transfer of signal between the two species is 
observed as the reaction occurs. Increasing amount of l-glutamate favours the E-PMP 
form at 330 nm. 
 At 100 µM of l-glutamate, the reaction with ArnB-PLP was achieved within 
seconds. An isosbestic point is observed at around 360 nm (as shown by the red arrow 
in figure 5.11) suggesting that ArnB-PLP is transformed into ArnB-PMP without any 
absorbing intermediate species. This isosbestic point value is similar to the one 
















































Figure 5.11. UV-visible spectra of the reaction between ArnB and increasing 
concentrations of l-glutamate (0 to 100 µM). Values were taken after 1 minute of 
reaction. 
 
 Six additional amino acids were tested as potential amine donor substrates; l-
asparagine, l-aspartic acid, l-glutamine, l-methionine, l-serine and l-cysteine. Among 
the six amino acids tested, l-methionine, l-cysteine and l-glutamine were the only 
aminoacids capable of reacting efficiently with ArnB-PLP. However, l-asparagine, l-
aspartic acid and l-serine demonstrated very little reactivity. If l-glutamate was the 
fastest amino acid tested, exceeding the limitation of our manual mixing studies (data 
not shown), l-glutamine was the second most reactive amino acid assayed. l-glutamine 
reached completion (full conversion to E-PMP) within few seconds in presence of 1 
mM of amino acid (Fig. 5.12). 
 L-methionine and l-cysteine were independently incubated at saturating 
concentration of 1 mM in presence of 10 µM of enzyme and spectra were scanned 
every 5 minutes. The time course of the half-reaction of ArnB aminotransferase with 
l-methionine is shown in Figure 5.13. The conversion of ArnB from its PLP form to 







































Figure 5.12. Formation of ArnB-PMP in the presence of l-glutamine (1 mM). Scans 




















Figure 5.13. Formation of ArnB-PMP in the presence of l-methionine (1 mM). Scans 
were taken every 5 minutes. 
 
 We perform the same experiment in the presence of l-cysteine (data not 
shown). To quantitatively compare the reactivity of l-methionine and l-Cysteine 
towards ArnB-PLP, kinetics of ArnB-PMP formation obtained in the presence of both 
amino acids were plotted on the same graph and fitted to a single exponential decay 
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Figure 5.14. Reactivity of l-methionine (red dots) versus l-cysteine (black dots) with 
ArnB-PLP over time. Both amino acids were added to a final concentration of 1 mM 
 
 For each time points, the ratio A420/A330 was calculated, normalised and 
plotted as function of time. Figure 5.14 shows the kinetics of ArnB-PMP formation in 
the presence of l-methionine (red) and l-cysteine (black). Solid curves are fits for a 
single exponential function (see chapter 6, section 6.2.5.2, equation 1). The observed 
rate constants for the l-methionine and l-cysteine were respectively 0.081 ± 0.0033 
min-1 and 0.066 ± 0.0061 min-1. The rate constant observed for the methionine is in 
agreement with the value reported for ArnB from S. typhimurium which was 0.051 ± 
0.013 min-1 [95]. 
 
5.4 Assays of ArnB with Potential Inhibitors 
 
In vitro inhibition tests of ArnB with various compounds were carried-out in order to 
screen potential inhibitors to perform in vivo studies consisting in killing assays 
towards various bacteria including pathogenic strains. 
 D-cycloserine (D-CS) and l-cycloserine (L-CS) were the first antibiotics to be 
tested since a previous study carried out analysis of the interaction of L-CS with ArnB 
from S. typhimurium [95]. The enzyme was incubated with 1 mM D-CS and 
monitored by UV-Vis. The reaction of D-cycloserine with the protein ArnB-PLP 
showed a different profile compared to those previously recorded with the L-amino 
acid substrates (Fig. 5.15). 
















































Figure 5.15. Time course of the reaction of ArnB with d-cycloserine (D-CS, 1 mM, 
scans were recorded every 12 seconds).  
 
 Upon incubation of B. cenocepacia holo-ArnB with D-CS the signal at 420 nm 
decreased immediately and a new peak appeared at around 370 nm with a broad 
shoulder between 330-360 nm (Fig 5.15). This suggested the formation of an 
inhibitor-ArnB complex. When 1mM l-glutamate was added to this reaction, the UV-
visible spectrum of the enzyme with bound d-cycloserine remained unchanged (data 
not shown), suggesting that an alternative amino donor could not displace the product 
formed between D-CS and ArnB. The same incubation was also performed with the l-










Figure 5.16. Time course of the reaction of ArnB with l-cycloserine (L-CS., 1 mM, 
scans were recorded every 6 seconds).  
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 By monitoring the UV-vis spectrum it was immediately clear that the 
behaviour of the ArnB in the presence of the L-CS enantiomer was different to that of 
the enzyme in the presence of the D-enantiomer. In contrast to D-CS, L-CS caused a 
rapid disappearance of the peak at 420nm and the appearance of a peak at 320 nm. 
Unlike the case with D-CS which was not instantaneous (relatively slow), these rapid 
changes caused by L-CS addition could be monitored between 0-60 seconds. It 
appears that ArnB reacts differently, and at different rates with each cycloserine 
enantiomer. Of interest, in the study by Noland and colleagues of the ArnB from S. 
typhimurium the UV-vis data presented was that of ArnB incubated with only L-CS – 
this was similar to our data of B. cenocepacia ArnB with D-CS. However, according 
to the file recorded in the Protein DataBank (PDB code (1MDZ) Noland et al 
determined the x-ray structure of the ArnB in complex with D-CS at 2.07 Å 
resolution. They interpret the electron density of the PLP adduct as a 
hydroxyisoxazole-PMP and state that the α-carbon of D-CS has apparent sp2 
hybridisation, consistent with the abstraction of the α-H by the general base Lys188. 
They also suggest that the sp2-hybridised α-carbon makes the cycloserine and PLP 
rings nearly co-planar in the adduct (see figure 5.17 below). However, it is interesting 
to note that in the rendered structure the α-H is still present in an oxazolidine adduct 










Figure. 5.17. The rendered J-mol structure of the S. typhimurium ArnB D-CS-PLP 
adduct taken from the ArnB 1MDZ. 
 
 Of further interest, Fenn and coworkers have reported that the two cycloserine 
enantiomers react with the PLP-dependent enzyme alanine racemase from Bacillus 
stearothermophilus (AR, EC 5.1.1.1) leading to the formation of the same PLP-
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cycloserine adducts (the hydroxyisoxazole-PMP derivative) [118]. The UV-vis data 
presented in this study were very similar to what we observed between B. 
cenocepacia ArnB and L-CS (Fig. 5.16). In alanine racemase it is thought that the 
formation of the same product PLP-inhibitor adduct from the enantiomeric pair of 
inhibitors can be accomplished by the presence of a complementary acid and base pair 
of residues in the active site of this racemase. Fenn et al also determined the structures 
of alanine racemase in complex with D-CS (PDB code: 1EPV) and L-CS (PDB code: 
1NIU). In both cases the authors suggest the cycloserine adducts are the 
hydroxyisoxazole-PMP and the α-carbon is sp2 hybridised. 
 In our study, based on the UV-vis data of the B. cenocepacia ArnB, we 
suggest that the final products are likely to be the same derivatives to that found with 
S. typhimurium ArnB since the two enzymes share 51% amino acid sequence identity 
with the active site residues conserved (Fig. 5.1). However, our UV-vis data is also 
consistent with the excellent study of the alanine racemase by Fenn et al. There is 
uncertainty in assigning definitive structures of the adducts. The signal at 320 nm can 
be interpreted as being due to either PMP or PMP-cycloserine adducts since they both 
have a maximum absorbance at around 330 nm. However, the broad peaks extending 
out to beyond 400 nm suggest the presence of a PLP-isoxazole adduct. To account for 
the possible formation of PMP (i.e. cycloserine acting as an amino donor) and the 
PLP-isoxazole we have postulated two possible mechanisms outlined in figure 5.18. 
 The mechanism depicting the formation of the hydroxyisoxazole-PMP 
derivative is adapted from Fenn et al and describes the initial transamination of the 
cycloserine molecule from the internal aldimine (holo-form) to generate an external 
aldimine. The lysine residue (Lys 186 in B. cenocepacia ArnB equivalent to Lys188 
in S. typhimurium ArnB) carries out a deprotonation at the -carbon position 
generating a quinonoid intermediate that is rapidly converted to the ketimine form. 
From the ketimine, we speculate a different mechanism to that proposed by Fenn et al 
[119] that could lead to the formation of an ArnB-PMP form and “free” isoxazole 
derivatives by hydrolysis (Fig. 5.17, B, C and C’).  
The reaction mechanism for the formation of the hydroxyisoxazole-PMP 
derivative is the other route suggested. It begins with the ketimine form which is 
deprotonated at the -carbon by the lysine residue leading to the formation of the 
product PMP-hydroxyisoxazole derivative A. This is the co-planar adduct observed 
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by Noland and coworkers in their crystal structure (Fig. 5.18, inset) [95]. Residues 
involved in the stabilisation of the PMP-cycloserine intermediate are highlighted in 
figure 5.18. The sequence alignment of ArnB from Salmonella and Burkholderia 
confirmed the presence of the same residues that stabilise the isoxazole PMP 








Figure 5.18. Proposed mechanisms of reaction between D-CS and ArnB. The 
structure is that of the S. typhimurium ArnB:hydroxyisoxazole-PMPcomplex (product 
A in box) (PDB code: 1MDZ). 
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 The interesting data obtained with the CS inhibitors encourage us to explore 
two other potential inhibitors; gabaculine and ibotenic acid, which are two 
neurotoxins (Fig. 5.19). Gabaculine is a well-studied chemical compound and acts as 
potent irreversible inhibitor against GABA (-aminobutyrate) transaminase, a PLP-
dependent enzyme [119]. Ibotenic acid is a neurotoxin found in mushroom from the 
genus Amanita. Unfortunately neither these two neurotoxins displayed any reactivity 
towards ArnB and after incubation with these compounds the UV-visible spectrum 
profile of the holo-form of the ArnB remained unchanged (data not shown).  
 
 





Figure 5.19. Chemical structures of ibotenic acid (A) and gabaculine (B)     
 
 It appears that although ArnB binds a range of amino acids and both CS 
enantiomers it does display some substrate selectivity. 
 
5 5 In vivo Antimicrobial Assays of D-Cycloserine and Polymyxin B 
 
Since d-cycloserine is a broad spectrum antibiotic used against tuberculosis 
(Seromycin, Lilly), and encouraged by the results obtained with the in vitro assays of 
recombinant B. cenocepacia ArnB we decided to perform antimicrobial tests with d-
cycloserine on a range of Burkholderia species. For cost reasons only D-CS was used 
since it is ~30 times less expensive than L-CS. As a control we also used polymyxin 
PMB, a cationic AMP. We first assayed the two compounds separately and then 
simultaneously in order to evaluate respectively their antibiotic and synergistic 
potential. Therefore, the minimum inhibitory concentrations (MICs) of both 
compounds were determined against numerous bacteria including E. coli, P. 
aeruginosa, B. multivorans and B. cenocepacia (Table 5.1). 
 Within these four bacteria species, different strains were tested and the MIC 
values were given according to the concentration for which no growth could be 
observed on the plate. Concerning PMB, the MICs observed for E. coli and P. 
A B 
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aeruginosa were very low with no visible growth after 0.25 µg/ml while d-cycloserine 
MICs were calculated to be from 20 to 64 µg/ml. On the other hand, d-cycloserine 
displayed the lower MIC values towards both Burkholderia genomovars (II and III) 
with values ranging from 6 to 40 µg/ml while a majority of such strains were still 
resistant above 500 µg/ml of PMB. 
 It is interesting to note that for strains unable to modify their lipid A with 
aminoarabinose - E. coli and P. aeruginosa - the MICs value for PMB are very low. 
In contrast, Burkholderia strains where such modification is constitutively expressed, 
the PMB action has little effect as expected but interestingly, cycloserine displayed 
relatively low MIC values. Although D-CS is a broad-spectrum inhibitor that could 
inactivate many PLP-dependent enzymes, the differences observed in killing between 
bacterial species is quite striking. 
 
Strain MIC 
Polymyxin B (µg/ml) 
MIC  
d-cycloserine (µg/ml) 
E. coli   
 


















B. multivorans  (II) 
 
    C5393 
    LMG 13010 
    C1576 
    CF-A1-1 
    JTC 
    C1962 





















B. cenocepacia  (III) 
 
    J2315 
    K56-2 













Table 5.1 Minimum inhibitory concentration (MIC) values for various strains of 
bacteria. MIC numbers given correspond to the first plate for which no growth could 
be observed. 
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 The combined action of cycloserine with PMB was assayed by the disc 
diffusion method on isosensitive agar (ISA) plate containing increased concentrations 
of PMB (see Chapter 6, section 6.2.7.1). Different quantities of cycloserine were 
spotted on the disc (10, 50, 100 and 250 µg) and put on plate previously inoculated 
with cell culture. These assays were performed on B. multivorans (LMG 13010 and 
ATCC 17616) and B. cenocepacia strains (SAL-1 and J2315) (Fig. 5.20). 
 For all strains tested, a dose-response is observed as the killing zone increase 
with the concentration d-cycloserine. Moreover, the additional effect of cycloserine 
with increased concentrations of PMB was observed for B. cenocepacia SAL-1 and B. 
multivorans ATCC 17616 strains as the killing zone around the disc increases when 
PMB is more concentrated (Fig. 5.20). 
 The same effect was not observed for Burkholderia strains LMG 13010 and 
J2315 where the killing zones around the disc remain unchanged despite the increased 
concentration of PMB. Moreover, no synergistic effect was observed between PMB 
and cycloserine.  
 These antimicrobial assays were carried out with K. Bodewits, PhD student at 
University of Edinburgh. 
 





















































































































































































Chapter 5: Characterisation of Enzymes Involved in Ara4N Biosynthesis (ArnB, ArnG) 
108 
5.6 Cloning, Expression and Purification of ArnG (BCAL 1930) 
 
Since no structural data was available on the ArnG protein the initial strategy was to 
clone the arnG gene in pET28a in order to express and purify the protein either with a 
hexa-histidine tag at the C-terminal and at the N-terminal of the gene sequence. 
 A PCR amplification was carried out to amplify the arnG gene from the 
genomic DNA of B. cenocepacia J2315. Primers were designed to insert NcoI/XhoI 
and NdeI/XhoI restriction sites in order to clone the gene with respectively a C- and 
N-terminal hexa-histidine tag in the pET28a vector plasmid After ligation of arnG 
gene into the target plasmid, pET28a-ArnG-CHis and pET28a-ArnG-NHis (Fig. 5.21) 















Figure 5.21. Plasmid map of pET28a-ArnG-NHis used to express and purify ArnG 
with a His-tag at the N-terminal. 
 
 After an overnight growth at 30ºC, cells were subcultured and further grown in 
universal tubes until the OD600 reached 0.6. Cells were induced with 0.5 mM IPTG for 
6 hours and 1 mL of each sample was kept for Western-blot analysis. At this stage 
only the visualisation of ArnG expression was wanted. Attempts to detect ArnG 
expression by SDS-PAGE analysis failed as the level of expression for such proteins 
is very low. Therefore, a western-blot analysis was performed on ArnG expression 
with an anti-His tag antibody and shown in figure 5.22. Lane A and B represent 
respectively the expression of ArnG with a poly his-tag at the C-terminus before and 
after induction with IPTG. In parallel, the same analysis was carried out with arnG 
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ArnG tagged at the C-terminus, the induced sample for ArnG with a histidine tag at 
the N-terminus could be visualised. These results suggest that the C-terminus 
sequence of ArnG could be embedded in the membrane, expression is very low, or the 




















Figure 5.22. Detection of C-terminal versus N-terminal His tagged ArnG expression 
by the western-blot method. Lanes A and C represent the expression before IPTG 
induction, lanes B and D is the cell extract after induction. 
 
 Using the same strategy but with a different tag at the N-terminus arnG gene 
was cloned into pET29a plasmid leading to a construct where ArnG was cloned with 
an S-tag .The expression of ArnG was also detected on a western-blot (data not 
shown). 
 A small scale expression and purification (20 mL) was carried out with 
BL21(DE3)PlysS cells freshly transformed with the pET28a-ArnG-NHis plasmid. 
After 6 hours of induction with IPTG, the cell pellet was resuspended in 1% SDS 
buffer and centrifuged for 10 minutes at 13 Krpm at 4 ºC. The cell extract was 
incubated 4 hours with Ni-NTA resin in presence of 20 mM imidazole, washed, and 
eluted with 100 mM and 250 mM imidazole. The different steps of expression and 
purification were monitored by western blot after separation of proteins on a Tris-
Glycine 16% precast gel (Fig. 5.23). Two samples were run side by side on the gel 
corresponding to a 0.5 mM and 1 mM IPTG induction. Induced samples were 
detected by western blot and two distinct bands could be visualised for both 
C-terminal His(6)-tag-ArnG N-terminal His(6)-tag-ArnG 
 M      A          B          M       C          D 
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inductions. Bands at around 15 kDa and 30 kDa which agree with the theoretical 
masses of the ArnG monomer and dimer were present after induction. After the 
washing step with 20 mM imidazole the sample was eluted with 100 mM imidazole 
revealing the two distinctive bands. No ArnG proteins could be detected after an 
elution step at 250 mM imidazole. Proteins present in the first elution sample were 
concentrated and run onto a Tris-Glycine 16% precast gel (Fig. 5.23, inlet). Two 
bands corresponding to those also detected by western blot are indicated by the two 
arrows. Contaminants were also present in the sample as shown in the higher section 


















Figure 5.23. Western blot analyses of the different step of purification of ArnG. The 
insert shows the precast gel profile of the sample after Coomassie blue staining. 
 
 Our results suggest that ArnG is expressed at very low levels and is extremely 
difficult to isolate in high yield and purity, which is expected for an inner membrane 
protein. Nevertheless, our results suggest that this method could be optimised further 
to isolate ArnG for structural studies. 
 
5.7 Complementation assay of ArnG in E. coli knock-out strains 
 
In the paper published by Yan and coworkers in 2007 [98], the E. coli MST100 strain 
which is able to constitutively modify the lipid A moiety of LPS and therefore be 
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(pmrL/M) responsible for the flippase activity of the undecaprenyl phosphate-
aminoarabinose. Hence, three new strains sensitive to PMB were created by replacing 
arnE (pmrL), arnF (pmrM) and arnE/F (pmrL/M) genes with a kanamycin cassette 
(respectively named AY100, AY101 and AY102). Another gene, arnT (previously 
pmrK), was knocked-out, leading to the AY103 construct. The ArnT protein carries 
out the last step of modification pathway of lipid A by attaching the modified sugar 
(aminoarabinose) to the 1 and/or 4’ phosphate of the lipid A moiety. The idea of the 
complementation assays was to transform the B. cenocepacia arnG gene in the 
different strains in order to restore the missing flippase activity in the E. coli mutants. 
Hence, successful complementation will restore the resistance towards PMB. The 
strains were kindly provided by Prof. Christian Raetz from Duke University Medical 
Center and analysed on agar plates (Fig. 5.24). If the MST100 strain was resistant to 
15 µg/ml of PMB (plate A), none of the knocked-out strains were capable of growth 
under these conditions. On the contrary, all strains were able to grow on a kanamycin 
plate (20 µg/ml) with the exception of MST100 which doesn’t contain the kanamycin 













Figure 5.24. Strains provided by Raetz were tested on agar plates supplemented with 
15 µg/ml of PMB (A), 20 µg/ml of kanamycin (B) and agar-only plate (C). 
 
 ArnG gene was cloned into the pTrc99a plasmid (ampicillin resistant) (Fig. 
5.25) with no tag in order to avoid any negative artifacts due to the presence of a 
supplementary sequence. pTrc99a is a low-copy number plasmid and is optimised to 
express low amounts of the protein (10-20 per cell) compared to pET plasmids. It is 
convenient for complementation studies as its action is more physiologically relevant 
than plasmids optimised for overexpression and purification. Hence pTrc99a-ArnG 
was used to transform the three different strains, AY100, AY101 and AY102. After 






A B C 
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subcultured and grown for 5 hours. The different optical densities at 600nm were 
normalised and the cultures diluted 4 times to a 10-4 dilution. Three µl of each culture 
was spotted on 6 different plates of various PMB concentrations (0-15 µg/ml). In 
addition, the same protocol was applied to the three strains alone but also transformed 
with a pTrc99a-FbpA plasmid (P. Bilton, PhD, University of Edinburgh, which 
expresses a ferric binding protein FbpA) in order to compare the complementation 
tests with controls. The results concerning the double knock-out AY102 strain are 
shown on figure 5.26. The 3 samples displayed the same sensitivity towards the 
different PMB concentrations and same results were observed for AY100 and AY101 
strains (data not shown) leading to the conclusion that ArnG did not complement the 











Figure 5.25. Plasmid map of pTrc99a-ArnG used for the complementation assays. 
 
It appears that despite the fact that B. cenocepacia J2315 ArnG is present on 
the arn operon and bears resemblance to the E. coli ArnE and ArnF flippase proteins 
it cannot confer polymyxin resistance on E. coli strains in which these homologs have 
been knocked out. Sequence analysis of ArnG suggests it is a hydrophobic protein, 
but maybe Burkholderia-specific. It is interesting to note that the arnG gene is co-
transcribed with ArnT in Burkolderia suggesting the Ara4N transfer to lipid A and 
flipping may be linked. It may be that functional ArnG expression in the E. coli 
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Figure 5.26. Complementation assays of AY102 transformed with pTrc99a-ArnG. 
Increasing concentrations of PMB (0 to 15 µg/ml) were used and a series of culture 
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5.8 Conclusions and Perspectives  
 
In this study the biosynthesis of the amino sugar aminoarabinose (Ara4N) and its 
transfer to lipid A in B. cenocepacia J2315 was investigated by analysis of two 
important proteins. The enzyme ArnB (encoded by the gene pmrH) which is the third 
enzyme of the pathway, was cloned with a hexa-histidine tag, expressed in E. coli and 
purified in high yield using two steps – metal-affinity and size exclusion 
chromatographies. UV-visible spectroscopic analysis confirmed the enzyme was a 
PLP-dependent aminotransferase reacting with l-glutamate to form the ArnB-PMP 
species. ArnB was also able to react with various amino acids such as l-cysteine, l-
methionine, l-glutamine but appeared not to use l-serine, l-asparagine and l-aspartic 
acid as substrates. In the well characterised S. typhimurium ArnB, Lys241 and Arg229 
appear to be the residues selective for the amine donor. We suggest the equivalent 
residues in the B. cenocepacia ArnB are Lys232 and Arg218. l-glutamate and l-
glutamine both share two methylenes in the side-chain. Therefore, the lysine and 
arginine residues could also act as selective “tweezers” discriminating the amine 
donor substrate according to its carbon backbone length. Despite the fact that in all in 
vitro studies, including those described here, l-glutamate is the most reactive substrate 
for ArnB, it remains to be proven as the physiological amine donor in the 
aminoarabinose lipid A modification pathway either for E. coli, S. typhimurium or B. 
cenocepacia.  
 We also incubated the recombinant B. cenocepacia ArnB protein in the 
presence of both the l- or d-enantiomers of cycloserine, a well-known inhibitor of 
many PLP-dependent enzymes. These generated different UV-visible spectra and 
reacted at different rates. By consideration of the previous work on S. typhimurium  
ArnB and the alanine racemase from B. stearothermophilus we propose two distinct 
mechanistic pathways leading to the formation of either a covalent hydroxyisoxazole-
pyridoxal amine phosphate adduct or the PMP form of the enzyme and “free” 
hydroxyisoxazole adducts. The inhibitor complexes are non-covalently bound in the 
enzyme active site. Further work could apply x-ray crystallography and mass 
spectrometry techniques to capture these proposed molecules. Since amino arabinose 
metabolism appears to be essential for Burkholderia, an inhibitor of an 
aminoarabinose biosynthetic enzyme should be a potent antimicrobial agent against 
these species. In vivo antimicrobial assays have shown that d-cycloserine was more 
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efficient than the antimicrobial peptide polymyxin towards Burkholderia species and 
could be explored as a potential new therapy for Cystic Fibrosis sufferers infected by 
pathogens that are resistant to other antibiotics.  
 The increased potency of D-CS over PMB towards Burkholderia species could 
be due to the unique feature shared by such species which is the constitutive 
modification of lipid A by aminoarabinose moiety. This unique phenomenom could 
be the Achilles’ heel of this and other pathogenic bacteria that cause lung damage and 
inflammation in cystic fibrosis patients. D-cycloserine targets ArnB, a key enzyme in 
this lipid A modification pathway. Moreover, these preliminary results open a new 
route for the development of promising therapeutics. However it appears that PMB is 
not a good candidate to use in combination with cycloserine. To date only three 
reported cases of cystic fibrosis patients with a “cepacia syndrome” survived after 
intravenous antibiotic therapy [120-122]. A mixture of different antibiotics including 
trimethoprim, tobramycin, meropenem and other antimicrobial compounds were 
necessary for the survival and recovery of these patients. Such chemical compounds 
could be tested alongside with cycloserine on clinical strains in order to evaluate a 
possible synergistic effect. So far the main clinical application of cycloserine is for the 
treatment of tuberculosis. 
 The second protein studied, ArnG, is an inner membrane protein which could 
act as a flippase of undecaprenyl phosphate-aminoarabinose just before the last step of 
the modification pathway of lipid A in B. cenocepacia. In E. coli two genes have been 
identified to be responsible for this flippase activity. ArnE and arnF have been shown 
to be critical for the translocation of the undecaprenyl phosphate through the inner 
membrane. Knock-out either or both of these two genes affected the resistance of the 
MST100 strains towards polymyxin B in E. coli. Attempts to recover the resistance 
phenotype in these sensitive mutant strains with the ArnG from B. cenocepacia, a 
natural PMB-resistant microorganism, failed in our hands. The expression and 
purification of ArnG was performed on small-scale and expression was only detected 
if the protein was fused with an N-terminal His-tag using a His-tag specific antibody. 
 Small hydrophobic proteins such as ArnE, ArnF or ArnG have similarities to 
proteins found in the small multidrug resistance protein family (SMR family). SMR 
proteins are 100-140 amino acids length, share a 4 transmembrane -helical domain 
and can act as homo- or hetero-oligomers. Moreover, SMR proteins are located in the 
inner membrane and confer resistance towards a variety of quaternary ammonium 
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molecules and cationic dyes [123]. Despite the fact that ArnG protein falls into the 
characteristics previously described, extreme care needs to be taken and further 
investigations to be performed to unambiguously attribute its function. 
 Future work should focus on investigating the synergistic effect of cycloserine 
with various partners in order to establish the most potent “mix” of antibiotics against 
diverse pathogenic bacteria. Concerning ArnG, a viable knock-out strain deleted for 
arnG gene in the B. cenocepacia J2315 genome will be very useful to repeat 
complementation assay with the plasmid used in this study. Moreover, the 
determination of the high resolution structure of such a protein may provide also 
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6.1 Material and Methods for Chapters 2 and 3 
 
6.1.1 General Materials 
 
6.1.1.1 General Reagents 
Solvents and chemicals were of the appropriate quality and were purchased from GE 
Healthcare, Sigma-aldrich, Promega, New England Biolabs, Pierce, BioRad, 
Vivascience, Anachem, Invitrogen, VWR International unless otherwise stated. 
 
6.1.1.2 Solutions and Media for Peptide and Protein Expression 
Buffers – All buffers were prepared fresh, as required, and were filtered with 0.2m 
filter before use. Buffers contents are described in the text where appropriate. 
Sterilisation of media – All media were autoclaved at 121 ºC for at least 15 min at 15 
psi prior to use. 
Agar plates – bacto-agar (15 g/L) was added to the specified media to prepare agar 
plates. 
Luria Bertani (LB) – tryptone (10 g/l), yeast extract (5 g/l), sodium chloride (10 g/l); 
pH adjusted to 7.5 with sodium hydroxide. 
2YT – tryptone (16 g/l), yeast extract (10 g/l), sodium chloride (5 g/l); pH adjusted to 
7.5 with sodium hydroxide. 
SOC – tryptone (20 g/l), yeast extract (5 g/l), sodium chloride (0.5 g/l), magnesium 
sulfate (5 g/l), glucose (3.2 g/l); pH adjusted to 7.5 with sodium hydroxide. 
Isosensitest agar (ISA) – 31.4 g dissolved in 1L dH2O (Oxoid Ltd.). 
Isosensitest broth (ISB) – 23.4 g dissolved in 1L dH2O (Oxoid Ltd.). 
S-Gal/LB/Amp plates: a pack of S-GalTM/LB Agar blend (Sigma) was dissolved in 
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6.1.1.3 Minimum Media for 15N-HBD2 Expression  
 
Table 6.1 Composition of minimum media M9 used in this study 
M9 medium     Final concentration in 3L total volume 
Na2HPO4     16 mM 
KH2PO4     7.4 mM 
NaCl      2.8 mM 
     
Fortification 
1 M MgSO5      2 mM 
50 mM CaCl2      0.10 mM 
50 mg/mL thiamine     0.12 mM 
50 mg/mL biotin     0.16 mM 
20% glucose      0.3% 
2M (15NH4)2SO4     7.6 mM 
15N-ISOGROTM     N/A (0.5 g/l) 
 
1000 x trace metals mixture: 
50 mM FeCl3 in 0.12 M HCl    50 µM 
20 mM CaCl2      20 µM 
10 mM MnCl2     10 µM 
10 mM ZnSO4     10 µM 
2 mM CoCl2      2 µM 
2 mM CuSO4      2 µM 
2 mM NiCl2      2 µM 
2mM Na2MoO4     2 µM 
2mM Na2SeO3     2 µM 
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6.1.2 Molecular Biology: DNA Manipulation 
 
6.1.2.1 Bacterial Cell Lines  
 
Table 6.2 Bacterial cell lines used in this study. 
Strain 
 
Genotype Description/ Applications 
BL21(DE3) 
 








F- omp Thsdsb (rB
- mB
-) gal 
dcm (DE3) pLysS (CamR) 
Expression host for 
expression of 15N-HBD2 
in E. coli. 
 
6.1.2.2 Oligonucleotide Primers for HBD2 
The following oligonucleotide primers were used in this study. 
 
Table 6.3. Oligonucleotide sequences used in this study. 








M1A For GCGGCAGCCATGCGCATACCCCAGAACACATC 
M1A Rev GATGTGTTCTGGGGTATGCGCATGGCTGCCGC 
M126A For GAATATTCACGCATGCCAGGCGCTGATGGGTATCGGTGAC 
M126A Rev GTCACCGATACCCATCAGCGCCTGGCATGCGTGAATATTC 
 
6.1.2.3 Cloning of HBD2 
Six overlapping primers (Table 6.3) with codons optimized for expression in E. coli 
were designed using the mature HBD2 amino acid sequence (also known as DEFB4, 
Genbank accession number, NM_004942). The reaction contained in a final volume 
of 100 l: 10 l (100 pmol) of the outermost 5’ primers (P1 and P6) of each strand, 10 
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l (10 pmol) of the internal primers (P2 – P5), 4 l DMSO, 10 l 10 x Herculase 
reaction buffer (Stratagene), 1 l Herculase Hotstart DNA polymerase (Stratagene), 4 
l 25 mM dNTPs, 21 l dH2O and was subjected to 30 PCR cycles of 95 ºC for 2 
minutes, 40 ºC for 3 minutes and 72 ºC for 30 seconds. A second amplification was 
performed to confirm annealing of all six primers in a final volume of 50 l: 5 l 
primer P1 (50 pmol), 5 l primer P6 (50 pmol), 2 l template, 38 l dH2O and 2 puRe 
Taq Ready-To-Go PCR beads were subjected to 30 PCR cycles of 95 ºC for 2 
minutes, 40 ºC for 3 minutes, 72 ºC for 30 seconds and a final extension of 72 ºC for 
10 minutes to add A overhangs. The PCR product containing the codon-optimized 
gene preceded by Met and flanking AlwN1 recognition sites was purified, cloned into 
pGEM-T Easy plasmid and a positive clone sequenced to confirm the fidelity of the 
insert. The target gene was then cut and ligated into the expression plasmid pET-31b 
(Novagen) to give pET-31b/HBD2. To incorporate a N-terminal His(6)-tag sequence, 
both pET-31b/HBD2 and pET-28a(+) vectors were cleaved by restriction enzymes 
NdeI and XhoI and the HBD2 fragment now containing the ketosteroid isomerase 
(KSI)-fused gene was cloned into pET-28a. To avoid CNBr cleavage at unwanted 
sites within the fusion residues Met 1 and 126 of KSI were replaced with Ala by site-
directed mutagenesis to give plasmid pET-28a/HBD2. The fidelity of this clone was 
confirmed by DNA sequencing.  
 
6.1.2.4 Cloning of HBD1 
A codon-optimised, synthetic HBD1 gene was purchased from CLONTECH and 
cloned alongside with the HisKSI sequence in the pUC19 vector. The HisKSI-HBD1 
fragment was cloned into the pET28a vector using NcoI and XhoI restriction sites. 
The pET-28a/HBD2 plasmid was used as a template and replaced the HisKSI-HBD2 
sequence with KSI-HBD1. 
 
6.1.2.5 Transformation of E.coli Competent Cells 
Competent cells were transformed according to the manufacturer’s instructions. DNA 
(up to 40 ng) was added to an aliquot of competent cells and gently mixed. This was 
left on ice for 15 minutes before the cells were heat shocked at 42 °C for 30 secondes. 
The cells were then grown in 80 or 250 µl SOC medium at 37 °C for 1 hr. Finally, the 
cells were spread to dryness on selective agar plates and incubated at 37 °C overnight. 
Chapter 6: Materials & Methods 
132 
6.1.2.6 Storage of Bacterial Stocks 
LB or 2YT medium containing the appropriate antibiotics were used for the short 
term storage of E. coli. Colonies of bacteria were stored on inverted agar plates at 4 
°C for up to one month. For long term storage strains were frozen (-80 °C) in LB or 
2YT media containing 20% glycerol. 
 
6.1.3 Peptide Expression and Purification 
 
6.1.3.1 Polyacrylamide Gel Electrophoresis (PAGE) 
SDS-PAGE (15% (v/v) acrylamide) was used to analyse proteins at different step of 
purification process on the basis of their molecular mass. The technique used was the 
discontinuous buffer system of Laemmeli. Alternatively, proteins were analysed on 
precast 12% Bis-Tris Nu-PAGE gels (Invitrogen) according to manufacture’s 
instructions. Gels were visualised using Coomassie blue. 
 
6.1.3.2 Large Scale Expression of HBD2  
Both pET-31b/HBD2 and pET-28a/HBD2 vectors were transformed into either 
BL21(DE3) or BL21(DE3)pLysS competent cells. After overnight growth on plate at 
37 °C a single colony was added to 250 ml of 2YT supplemented with 100 µg/ml 
ampicillin (pET-31b/HBD2) or 30 µg/ml kanamycin (pET-28a/HBD2). This 
preculture was shaked overnight at 37 °C and 350 rpm. It was then used to inoculate 3 
litres of fresh growth medium which was incubated until cells reached an absorbance 
A600 = 0.5 where the medium was supplemented with isopropyl-1-thio-β-D-
galactopyranoside (ITPG) to a final concentration of 1 mM. After a further 6 to 7 
hours the cells were harvested by centrifugation (5000 rpm for 15 minutes at 4 °C), 
and the supernatant discarded. The HisKSI-HBD2 expressing pellet (yellowish 
colour) was collected, weighed (7 to 12 g) and frozen at -20 °C before extraction and 
purification. 
 The same method was applied for the expression of HBD1. 
 
6.1.3.3 Large Scale Expression of 15N-HBD2  
The E. coli strain BL21(DE3) containing the plasmid pET-28a/ HBD2 was grown in 6 
x 6 mL of 2X YT medium containing 30 lg/ml kanamycin at 37 °C. Once the OD600 
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reached 0.6–0.8, cells were centrifuged (3000 rpm for 10 min, 4 °C) and the 
supernatant was removed. The pellet was washed and re-suspended in M9 minimal 
medium three times, and the combined suspensions were added to 3 L fortified M9 
minimal medium with 30 µg/ml kanamycin. The summary of the components used in 
the fortified minimal medium is presented in Table 6.1. The 3 L of culture were 
divided into 6 x 1 L flasks with approximately 500 mL in each and shaken at 30 °C. 
When the A600 reached 0.5, protein expression was induced by 1 mM isopropyl-b-D-
1-thiogalactopyranoside (IPTG) and the cells were further incubated for 6 h. Cells 
were isolated by centrifugation (5500 rpm for 12 min, 4 °C). From 3 L of culture, 
approximately 7 g of wet weight E. coli paste was obtained. 
 
6.1.3.4 Purification and Solubilisation of Inclusion Bodies 
All centrifugation steps were carried out for 20 minutes at 11000 rpm and 4 ºC. The 
cell pellet containing highly expressed HisKSI-HBD2 was suspended in 5 mL/g in re-
suspension buffer (50 mM Tris, 25% sucrose, 1 mM EDTA, 0.1% sodium azide, 10 
mM DTT, pH 8.0), before addition of 50 mg/mL lysozyme, 500 mM MgCl2 and 10l 
DNase. After incubation for 30 minutes at room temperature, lysis buffer (50 mM 
Tris, 1% Triton X-100, 100 mM NaCl, 0.1% sodium azide, 10 mM DTT, pH 8.0) was 
added (5 mL/g wet weight original pellet) and incubated for 45 minutes at room 
temperature. To this cloudy suspension, EDTA (500 mM) was added to give a final 
concentration of 1 mM, and the sample was snap-frozen in liquid N2 before 
immediately thawing for 30 minutes in a 37 ºC water bath. To this thawed extract, 
MgCl2 (500 mM) was added to give a 1 mM final concentration and the sample was 
incubated at room temperature for 1 h to allow the viscosity to decrease before 
centrifugation. The supernatant was discarded and the pellet from this step was re-
suspended in an appropriate volume of buffer (50 mMTris, 1% Triton X-100, 100 
mM NaCl, 1 mM EDTA, 0.1% NaAzide, 1 mM DTT, pH 8.0), sonicated for 4 x 30 
second blasts and centrifuged. The resulting pellet was then washed in 1 M Guanidine 
HCl buffer (1 M GuHCl, 50 mM Tris, 1% Triton X-100, 100 mM NaCl, 1 mM 
EDTA, 0.1% sodium azide, 1 mM DTT, pH 8.0), sonicated with 4 x 30 second bursts 
and centrifuged. The resulting pellet (inclusion bodies containing highly enriched 
KSI-HBD2) was re-suspended in ~ 50ml 6 M GuHCl binding buffer (6 M GuHCl, 50 
mM Tris, 10 mM imidazole, 500 mM NaCl, 5 mM -mercaptoethanol, pH 8.0). 
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Concerning the preparation with the pET-31b plasmid (KSI-HBD2), after 
resuspension with 6 M GuHCl (no imidazole), the solution was directly 
supplemented with CNBr (see next chapter). For HisKSI-(15N-)HBD2 sample, the 
re-suspended solution was added to 10 ml pre-equilibrated nickel-nitrilotriacetic acid 
(Ni-NTA, Qiagen) agarose affinity resin, mixed by rotation for 1 h at 4 °C, then 
decanted into an empty 25 ml column reservoir. The packed resin was washed with 6 
M GuHCl binding buffer (50 ml) and then eluted with 25 ml of elution buffer (6 M 
GuHCl, 50 mM Tris, 120 mM imidazole, 500 mM NaCl, 5 mM -mercaptoethanol, pH 
8.0). This elution step with 120 mM imidazole was then repeated to give 50 ml of 
purified HisKSI-HBD2. The eluted fusion protein was dialyzed (Snakeskin dialysis 
tubing 3 kDa cut-off from Pierce) against 25 mM Tris buffer, pH 8.0 overnight at 4 ºC 
which caused precipitation of the fusion protein. 
 The same protocol was applied for HBD1 purification. 
 
6.1.3.5 CNBr Cleavage of the Fusion Tag 
The fusion was recovered by centrifugation and the pellet was re-suspended in 6 M 
GuHCl, 25 mM Tris buffer, pH 8.0. To this HCl (5 M stock) was added until the pH 
was ~1.0. Solid CNBr was added to give a final concentration of 250 mM and 
cleavage was allowed to proceed for 24 h in the absence of light and under nitrogen. 
The cleaved mixture was evaporated at 42 oC using a rotary evaporator to remove any 
unreacted CNBr, and the concentrated sample was dialyzed against 25 mM Tris 
buffer, pH 8.0 overnight at 4 oC to cause precipitation of the KSI. The precipitate was 
removed by centrifugation and the supernatant containing the peptide was filtered 
(0.45 M) and purified by FPLC or RP-HPLC. 
 
6.1.3.6 Purification of HBD2 by FPLC 
FPLC was performed on an Amersham Biosciences AKTA purifier 900. Samples 
were run onto a strong cationic Mono S 5/50 GL column (Amersham biosciences). A 
linear gradient was applied from 100 % 25 mM Tris buffer, pH 8.0 to 100 % 25 mM 
Tris, 1 M NaCl buffer, pH 8.0 at a flow rate of 0.5 ml/min. 
 
6.1.3.7 Purification of Defensins by Semi-Preparative RP-HPLC 
Semi-preparative RP-HPLC on a Jupiter™ Proteo column was performed with a 
Waters 600 control pump fitted with a photodiode array 996 detector using Millenium 
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32 software. The HBD2 isolated from the CNBr cleavage step was applied to the 
column in 3-4 ml batches, the column was washed with 5% acetonitrile (ACN) then a 
linear gradient of 5-55% acetonitrile over 50 minutes at a flow rate of 3 mL/minute 
was used to elute the HBD2. Fractions were analysed by SDS-PAGE and those 
containing HBD2 were pooled and analysed by ESI-mass spectrometry as described 
in section 6.1.4.4. 
 
6.1.3.8 Oxidation of Recombinant HBD2 
The HBD2 recovered by semi-prep-HPLC was freeze-dried then reconstituted in 25 
mM Tris, pH 8.0, with 20 mM tris(2-carboxyethyl)phosphine (TCEP) added to 
convert the peptide to the fully reduced form before re-purification by prep-HPLC 
using identical conditions as above. Fractions containing HBD2 were freeze-dried 
then dissolved in 50 mM Tris, pH 8.0, 3 mM cysteine, 0.3 mM cystine and stirred for 
4 h at room temperature. The reaction was followed by analytical RP-HPLC and 
analysed by ESI-mass spectrometry to confirm that the HBD2 was present in the 
oxidized form (elution at 40 mins). The final yield of oxidized β-HBD2 is 3-6 mg 
from 3 litres of E. coli culture (based on 10 preparations). 
 
6.1.4 Peptide Characterisation 
 
6.1.4.1 BCA Assay 

The concentration of defensins was calculated using a BCATM protein Kit Assay 
(Pierce) according to the manufacturers instructions. Breiefly, this assay is a 
detergent-compatible formulation based on bicinchoninic acid (BCA) for the 
colorimetric detection and quantification of total protein. A standard curve was 
assayed with different concentrations of bovine serum albumin (BSA) and the sample 
was referenced from this standard curve. The concentration of BSA and sample was 
read at 562 nm. 
 
6.1.4.2 Iodoacetamide Modification of HBD2 
Iodoacetamide assay is used to assess the ability for modification of free thiols in 
proteins and peptides. Iodoacetamide is a sulfhydryl alkylating reagent with a 
prosthetic group that irreversibly and covalently modifies cysteine residues. 
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 The assay was performed as follows: Iodoacetamide (4ul, 1 M made up in 1 M 
NaOH) was added to 200 µl of peptide sample (0.5 mg/ml) and incubated for 30 
minutes in the dark at room temperature. Excess of iodoacetamide was removed by 
PD10 column chromatography (GE Healthcare) with Tris 25 mM buffer, pH 8. the 
sample was further analysed by LC-ESI-MS. 
 The iodoacetamide modified peptide yields a 57 Da mass increased on LC-
ESI-MS. 
 
6.1.4.3 Protease Digestion and Peptide Mass Mapping of Defensins 
Chemotrypsin and trypsin (0.5 mg/ml each) were used for the enzymatic digestion of 
50 l of HBD2 (1 mg/ml). The reaction was performed overnight at 37 oC in 50 mM 
Tris buffer containing 0.005% Triton X-100 and 20 mM NaCl, pH 8.3. TFA 0.05 % 
was then added to terminate the reaction and the cleaved product injected onto a 
Phenomenex Jupiter 4µ Proteo 90A column (250 x 2.00 mm) coupled with an ESI-
MS spectrometer. The gradient used was 10 to 35 % ACN at a flow rate of 0.2 
ml/min.  
 The two-disulfide bridged peptide fragment was extracted, freeze-dried and 
subjected to one-step manual Edman degradation. The peptide was re-suspended in 
200 l water/pyridine (1:1) and 10 l of PITC was supplemented. The solution was 
incubated 30 min at 50 °C to remove the solvent and 100 l of TFA was then added to 
cleave the N-terminal residue(s). The cleavage reaction proceeded at 50 °C for 15 
min, followed by removal of TFA under vacuum and re-suspension in 100 l water. 
Pentane/ethyl acetate (4:1) was used to wash (extract) the reaction mixture, and the 
aqueous phase was analyzed by LC-ESI-MS. The Edman degradation protocol was 
based on previous study from ref. [102]. 
 
6.1.4.4 Liquid Chromatography-Electrospray Ionisation Mass 
Spectrometry (LC-ESI-MS). 
LC-MS was performed on a MicroMass Platform II quadrupole mass spectrometer 
equipped with an electrospray ion source with a cone voltage ramped from 40 to 70 
V. The source temperature was set at 140 °C and peptide samples were separated with 
a Phenomenex Jupiter C18 reverse phase column (5 m, 250 x 4.6 mm). Typically, 
separation was achieved using a 20-50% acetonitrile (containing 0.01% TFA) 
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gradient at a flow rate of 1 ml/min over 60 min. The total ion count in the range 600-
2000 m/z was scanned at 0.1 s interval. The scans were accumulated, spectra 
combined and the molecular mass determined by the MaxEnt and Transform 
algorithms of the Mass Lynx software (Micromass, U. K.). 
  
6.1.4.5 Fourier Transform-Ion Cyclotron Resonance (FT-ICR)  
Characterisation of the recombinant 15N HBD2 peptide was performed using the 
accurate mass capabilities of a 9.4 T Apex III Fourier transform ion cyclotron 
resonance (FT-ICR) mass spectrometer (Bruker Daltonics, Billerica, MA). Nano-ESI 
was performed using a TriVersa Nanomate running in infusion mode and operated in 
the positive mode. Prior to analysis, peptides were reconstituted to a final 
concentration of 5 M in 50:49:1 MeOH: water: formic acid. The isotopic abundance 
was predicted using published methods within the XMASS and DataAnalysis 
software (Bruker). 
 
6.1.4.6 NMR Spectroscopy 
One mg of oxidized HBD2 was dissolved in 20 mM sodium acetate buffer, pH 4.0 at 
25 oC and 10% D2O (v:v) was added to give to a final peptide concentration of 0.46 
mM. 
 The 1D 1H NMR Spectrum of HBD2 was recorded on a Bruker AVANCE 
spectrometer equipped with a cryoprobe operating at 600 MHz and 25 °C. 128 scans 
were taken with a sweep width of 15 ppm and 8000 complex points. For water 
suppression double-pulsed gradient spin echo was used. The same protocol was used 
for HBD1. 
 15N labelled HBD2 (0.5 mg) was dissolved in 0.45 mL 20 mM sodium acetate 
buffer and 0.05 mL D2O to a final concentration of 0.23 mM and final pH of 4.7. All 
NMR spectra were recorded on a 600 MHz Bruker AVANCE instrument equipped 
with a cryoprobe and operating at 25 oC. For 1D spectra, 128 scans were taken with a 
spectral width of 15 ppm and 8000 complex points. Double pulsed field gradient spin 
echo was used for water suppression. For the 1H–15N HSQC experiment, 8 scans were 
taken for each increment, using acquisition times of 125 ms to sample both F1 and F2 
dimensions. For both the 3D HSQC-TOCSY and 3D HSQC-NOESY, spectral widths 
of 11, 17 and 17 ppm were used in 1H (indirect), 15N and 1H (direct) dimensions, 
respectively. WATERGATE suppression was used for both experiments. For both 
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spectra, 192 and 2048 complex points were acquired in F1 and F3, respectively. In F2, 
48 and 40 complex points were collected for the TOCSY and NOESY experiments, 
respectively. The relaxation delay was set to 1.3 s for both and the mixing time was 
70 ms for the TOCSY and 150 ms for the NOESY. 
 
6.1.4.7 Antimicrobial Activity Assay 
The purified, oxidized HBD2 was dissolved into 0.01% acetic acid and centrifuged 
(13000 rpm for 10 minutes, 25 °C) to remove precipitate. The HBD2 was 
concentrated (Vivaspin 0.5 ml concentrator, 3000 MWCO PES) to 1 mg/ml and stock 
HBD2 solutions of concentrations 15, 30, 60, 125, 250 and 500 g/ml were prepared. 
Antimicrobial assays were carried out according to the method set out in our previous 
study [36]. Briefly, a laboratory strain of E. coli K-12 MG1655 was grown to 
midlogarithmic phase (OD at 600 nm = 1.0). From this 90 l of E. coli (~1.0 x 105 
cells) culture was incubated with 10 l of each stock of HBD2 solution and as a 
negative control 90 l E. coli was incubated with 10 l of sterilised water containing 
0.01% acetic acid. These samples were incubated at 37 °C for 2 hours. Then 10-fold 
serial dilutions of the incubation mixture were plated on Iso-Sensitest plates, 
incubated at 37 °C, and the CFU was determined the following day. Colonies were 
counted and the LD50, LD90 (Lethal Dose: amount of peptide required to kill 50% 
and 90% of viable cells) and the MBC99.99 (Minimum Bactericidal Concentration at 
99.99%) values were calculated from the resulting killing curve. The same 
antimicrobial assays were performed with Pseudomonas aeruginosa (PAO1), a Gram-
positive strain Staphylococcus aureus (ATCC 25923) and a fungus, Candida albicans 
(J2922). In parallel, the same strains were used with the antimicrobial agent 
Polymyxin B (PMB) as a control. All the killing assays were performed at least 3 
times for each strain and the values were obtained by taking the mean of at least 3 
experiments. 
 
6.1.5 Surface Plasmon Resonance (SPR)  
 
6.1.5.1 Preparation of SPR Samples 
All lipids were purchased from Avanti Polar Lipids. Lipids vesicle were prepared as 
follows; typically, appropriate amount of lipids (in powder form) were re-suspended 
in 100% chloroform with the exception of POPE/Kdo2 lipid A mixture which was re-
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suspended in chloroform and methanol (8:2, v/v). Chloroform and/or methanol were 
evaporated under a gentle stream of nitrogen gas for 2 hours and then placed under 
vacuum pump overnight to remove any trace amounts of solvent. Dried lipids were re-
suspended in 10 mM HEPES buffer containing 50 mM NaCl and 1 mM EDTA, pH 
7.5. The solution was vortexed for 1 min and the lipid suspension was extruded with 
an Avanti mini-extruder through a 100 nm polycarbonate membrane according to the 
manufacturer’s instructions.  
 HBD2 peptide was re-suspended in filtered water and aliquots of 1.25, 2.5, 5 
and 10 M were prepared. 
 
6.1.5.2 SPR Experiments 
SPR was performed on a BiaCore T100 instrument with a L1 sensor chip (BiaCore). 
The “desorb and sanitize” protocol was used to clean the system with a maintenance 
chip and then allowed to run overnight with water. The L1 chip was docked in the 
system and first washed with an injection of 5 l of 20 mM nonionic detergent (Octyl 
-D-glucopyranoside) at a flow rate of 5 l/min in order to clean the chip surface. The 
extruded lipid solutions were then applied to all three flow cells on the chip surface 
simultaneously with injections of 80 l at a low flow rate of 2 l/min. In order to 
remove any mutilamellar structures from the lipid surface and to stabilize the 
baseline, 30 l of 10 mM NaOH was injected at 50 l/min. The peptide solution (100 
l) was then injected onto the model membrane surface at a flow rate of 30 l/min, 
having a total injection time of 200 seconds. On completion of injection, buffer flow 
continued to allow a dissociation time of 600 s. All binding experiments were carried 
out at 30 °C. All solutions were freshly prepared, degassed, and filtered through a 0.2 
m filter. Each sample was run in duplicate. 
 
6.1.6 Solid Phase Peptide Synthesis of HBD1 
 
 The chemical synthesis of HBD1 was carried out on an Applied Biosystems 
model 433A peptide synthesizer using a pre-loaded Fmoc-Lys(Boc) NovaSyn®TGT 
resin. Fmoc amino acids were purchased from Novabiochem. LC-Mass spectra 
confirming the identity and purity were obtained on a Micromass Quattro LC mass 
spectrometer. Semi-preparative HPLC was performed using a Phenomenex Luna C18 
column and a gradient of 5-95% acetonitrile (containing 0.1% TFA) over 45 minutes 
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(flow rate of 3 ml/min). All other chemical reagents were obtained from Aldrich. 
Automated solid-phase peptide synthesis was carried out on a 0.05 mmol scale using 
0.5 mmol of each Fmoc amino acid per coupling reaction and HBTU/HOBt as 
coupling reagents. The coupling time was 30 minutes. Peptide products were cleaved 
from the resin by exposure to 95 % TFA, 2.5% ethanedithiol, 2.5% water for 3 h. 
After this time, the resin was filtered-off, washed with TFA, and the filtrate was 
poured into diethylether (10 volumes). The precipitated peptide was then collected by 
centrifugation (3000 rpm, 15 minutes). The precipitate was re-suspended in ether (5 
volumes) and collected by centrifugation once again (3000 rpm, 15 minutes). The 
crude peptide was dissolved in water and loaded directly onto a semi-preparative 
HPLC column. Fractions containing the peptide products were identified by mass 
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6.2 Material and Methods for Chapter 5 
 
6.2.1 General Materials (see section 6.1.1) 
 
6.2.2 Molecular Biology: DNA Manipulation 
 
6.2.2.1 Bacterial Cell Lines  
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Used For transforming 
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(rk-, mk+) gal- phoA supE44 - 
thi-1 gyrA96 relA1  




F- omp Thsdsb (rB
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F- omp Thsdsb (rB
- mB
-) gal dcm 
(DE3) pLysS (CamR) 
Expression host for 
expression of 15N-HBD2 
in E. coli. 
MST100 W3110, lacU169 gal490 cl857 
(cro-bioA) pmrAc 
[98] 
AY100 MST100, pmrL::kan, Kanr Complementation assays 
[98] 
AY101 MST100, pmrM::kan, Kanr Complementation assays 
[98] 
AY102 MST100, pmrLM::kan, Kanr Complementation assays 
[98] 
AY103 MST100, arnT::kan, Kanr [98] 




Table 6.5. Plasmids used for cloning and expression in this study 
Plasmid Characteristics Source/reference 
pGEM-T-Easy Cloning vector (AmpR) Promega 
pET22b Expression vector (AmpR) Novagen 
pET28a Expression vector (KanR) Novagen 
pET29a Expression vector (KanR) Novagen 
pTrc99a/FbpA Complementation vector, low 
copy number. Apr Ptrc rrnB TtT2 
ori (pBR322) lacIq  
P. Bilton 
 
6.2.2.3 Oligonucleotide Primers 
The following oligonucleotide primers were used in this study. Restriction sites are 
highlighted in bold character. 
 
Table 6.6. Oligonucleotide sequences used in this study. Mutant codons and 
restriction sites are shown in bold. 
 
Primers Sequence 5’- 3’ 
arnB For (NdeI) CGCCATTACAGGCCAAACGCGCATATGAGC 
arnB Rev (HindIII) CAAGGTGACTCATGTACGCAAGCTTTCCGTATTG 
  
arnG For (NcoI) CCATGGACCCCGTTTCGTTCGTCTGCATCGT 
arnG Rev (XhoI) CTCGAGGCTGCGCGCGAGCACGAGCACA 
arnG For (NdeI) TGATCGTCGAGAAACCGCAATCGTAAGGACGCCTCC
CATATG 





6.2.2.4 Gene Amplification 
The PCR was carried out using two puReTaq Ready-To-Go beads (GE Healthcare), 
5l of each primer, 3 l J2315 chromosomal DNA and 37 l H2O. Samples were 
amplified for 25 cycles at 95 °C 1 min., 65 °C 1 min., 72 °C 2 min., with the initial 
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cycle of 95 °C 2 min. and final cycle 72 °C 10 min. (using a Perkin Elmer DNA 
thermal cycler). 
 
6.2.2.5 Gel Electrophoresis of DNA 
To make a 1% agarose gel, 1 g Agarose (Fisher Scientific) was added to 100 ml TAE 
buffer (Tris-Acetic acid-EDTA; 1X TAE buffer (50X stock diluted in H2O) 
containing 40 mM Tris-HCl, 20mM Acetic acid, 1M EDTA, adjusted to pH 8.3) and 
boiled by heating in a microwave until totally dissolved. The solution was then cooled 
before the addition of ethidium bromide (10 µl). The gel was poured into a casting 
mould and allowed to set at room temperature. 
 Added into the first well was 7.5 l molecular DNA marker hypperladder I 
(Promega), 2.5 l DNA 5 X loading buffer (Bioline) was added to 10 l PCR 
products, which was added to the adjacent well. The gel was run at 100V until 
markers showed sufficient separation. 
 DNA purification from the agarose gel was carried out following a QIAprep® 
Gel Extraction kit from Qiagen according to the manufacturer’s instructions. 
 
6.2.2.6 Cloning 
The purified DNA PCR product (3 l) was then ligated with 1 l pGEM T-Easy 
plasmid in 5 l of 2X ligation buffer and 1 l T4 DNA ligase. It was left overnight at 
4 °C. 
 The ligated product (2 l) was used to transformed suitable competent cells. 
SOC buffer (80 l) was inoculated with transformed cells and the broth was shaked at 
37 oC for one hour at 250 rpm and then spread on an S-Gal/Amp plate and left at 37 
°C overnight.  
White colonies were picked from plate and inoculated with 5 ml LB broth, 5 l 
ampicillin and grown overnight at 37 °C at 250 rpm.  
 The cells were spin down by centrifugation (using accuSpinTM Micro 
centrifuge). The plasmid DNA from the overnight culture was purified using 
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6.2.2.7 Digestion of DNA with Restriction Endonucleases 
The required amount of DNA (0.5-1 g) was incubated with the appropriate amount 
of endonuclease and with the relevant buffer for at least 2 hours at 37 °C. The sample 
was then subjected to electrophoresis on agarose. The gels were viewed and 
photographed under UV-light. 
 
6.2.2.8 Cloning into Plasmid Vectors 
The DNA fragment cut with suitable restriction enzymes  (13 l), the host vector cut 
with suitable restriction enzymes (4 l), 10x T4 DNA ligase buffer (2 l), and T4 
DNA ligase (2 l) were gently mixed and incubated overnight at room temperature. 2 
µl of the reaction mixture was used to transform suitable competent cells. 
 
6.2.2.9 DNA Sequencing 
The different cloned plasmids were sequenced according to a PCR-based method 
using BigDye®Terminator v3.1 (Apllied Biosystems). Each sequencing reaction 
typically contained: 5 l plasmid DNA, 1 l forward or reverse primer, 2 l BigDye 
and 2 l of 5X sequencing buffer.  The reaction was performed on an Eppendorf 
Mastercycler Personal hot-lid DNA thermal cycler and cycled 30 times at 94 °C for 
30 sec, 45 °C for 15 sec and 60 °C for 4 min. The reaction was submitted to the 
Institute for Cell and Molecular Biology service (ICMB) at University of Edinburgh 
for sequencing. Sequence data was analysed using Contig Express within the Vector 
NTI AdvanceTM V9 software package (Invitrogen). 
 
 
6.2.3 Cells Competency 
Two methods were used to make AY100, AY101 and AY102 strains competent. All 
buffers and disposable plasticwares were previously cooled down on ice. 
 
6.2.3.1 Chemical Competent Cells 
Freshly prepared LB broth (100 ml) was supplemented with the appropriate antibiotic 
and inoculated with 1 ml of overnight pre-culture. Cells were grown at 37 oC until 
OD600 reached 0.6 and then cooled down on ice for 30 minutes. They were then 
transferred to 50 ml falcon tubes and centrifuged at 6000 x g for 10 minutes at 4 oC. 
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Cell pellet was re-suspended in ice cold 10 mM Tris with 50 mM NaCl (pH 8.0) and 
pelleted again. The pellet was re-suspended in 50 ml (half of the original LB broth 
volume) 30 mM CaCl2 and placed on ice for 20 minutes. Cells were centrifuged and 
gently re-suspended in 1/20th of the original volume of 30 mM CaCl2. Finally, 
aliquots of 200 l were immediately flash frozen in liquid nitrogen and store at -80 oC 
until further use. 
 
6.2.3.2 Electro-Competent Cells 
Freshly prepared 2YT broth (200 ml) was supplemented with the appropriate 
antibiotic and inoculated with 2 ml of overnight pre-culture. Cells were grown at 37 
oC until OD600 reached 0.6 and then cooled down on ice for 30 minutes. They were 
then transferred to 50 ml falcon tubes and centrifuged at 6000 x g for 10 minutes at 4 
oC. The pellet was washed 3 times with ice cold sterile dH2O and transferred to a 15 
ml falcon tube. Cells were further washed with sterile dH2O containing 10 % glycerol 
(v/v) and centrifuged (6000 x g for 10 minutes at 4 oC). Finally, cells were gently re-
suspended in 5 ml of sterile dH2O with 10 % glycerol (v/v). Aliquots of 200 l were 
immediately snap frozen and store at -80 oC until further use. 
 
6.2.3.3 Electroporation 
Two to three l of plasmid DNA was placed in a 0.2 cm cuvette (Sigma-aldrich) and 
100 to 200 l of appropriate competent cells were added. The cuvette was then placed 
in the electroporator (EasyjecT plus, EQUIBIO, Flowgen) and cells subjected to 
electroporation (2500 V, 25 µF, 99 	). SOC (500 µl) was added immediately and the 
mixture was shaked for 1 hour at 30 oC. The culture was then spread onto LB agar 
plate containing the appropriate antibiotics and incubated overnight at 30 oC. 
 
6.2.4 Peptide Expression and Purification 
 
6.2.4.1 Polyacrylamide Gel Electrophoresis (PAGE) 
SDS-PAGE (15% (v/v) acrylamide) was used to analyse proteins at different step of 
purification process on the basis of their molecular mass. The technique used was the 
discontinuous buffer system of Laemmeli. Alternatively, proteins were analysed on 
precast 16% Tris-Glycine Precast gels (Invitrogen) according to manufacture’s 
instructions.  
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6.2.4.2 Large Scale Expression of ArnB 
Two l of  pET22bArnB plasmid was transformed into E. coli BL21(DE3) competent 
cells and left on ice for 30 minutes. The mix was heat shocked at 42 °C for 30 seconds 
and then put back on ice for 2 min. SOC media (80µl) was added to the cells and 
shaked for 1 hour at 37 °C at 250 rpm. The cells were then spread on an ampicillin 
plate and left overnight at 37 °C. A colony was picked, added to 200 ml LB broth and 
grown overnight at 37 °C. 
 The overnight pre-culture was added to 3L LB broth with a starting OD of 0.1. 
Cells were grown at 37 °C until an optical density (OD600) of 0.6-0.7 was achieved. 
The cells were induced with 0.5 mM IPTG for 5 hours and then spun down by 
centrifugation at 7000 rpm for 10 minutes at 4 ºC resulting in 10 g of cell pellet.  
 
6.2.4.3 Purification of ArnB 
Cell pellet was resuspended in 50 ml binding buffer (20 mM Kphos, 150 mM NaCl, 
25 M PLP, 15 mM imidazole, pH 8.0) as approximately 4 ml of binding buffer per 
gram of pellet is required. A Protease Inhibitor Tablet (Roche diagnostic, GmbH 
complete EDTA free) was added and left to dissolve. After 30 minutes on ice, cells 
were sonicated (Soniprep 150) for 15 minutes with 30 seconds on and off. The split 
cell was centrifuged at 14 krpm for 1 hour (DuPont Instruments). The cell free extract 
(CFE) was then filtered with a 0.45 m filter. 
 Nickel Sepharose resin (Amersham Biosciences) was prepared by 
resuspending the resin in the stored solution. The slurry (4 ml) was centrifuged for 5 
minutes at 3000 rpm and the supernatant discarded. The resin was washed with 10 ml 
water and centrifuged for 5 minutes at 3000 rpm with the supernatant being removed. 
This step was repeated once and the beads were resuspended in 20 ml of binding 
buffer (20 mM Kphos, 150 mM NaCl, 25 M PLP, 15 mM imidazole, pH 8.0), 
centrifuged for 5 minutes at 3000 rpm and supernatant removed. 
 The cell free extract was then added to the Nickel Sepharose beads, loaded 
into the column (Qiagen Polypropylene Column) and washed with 20 ml of binding 
buffer at 1 ml/min using a peristaltic pump (Minipuls3, Gilson). Three eluting buffers 
were used to isolate the protein, 20 ml of eluting buffer 1 (20 mM Kphos, 150 mM 
NaCl, 25 M PLP, 50 mM imidazole, pH 8.0) was added to the column. Then 20 ml 
eluting buffer 2 (20 mM Kphos, 150 mM NaCl, 25 M PLP, 100 mM imidazole, pH 
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8.0) was added to elute the protein. Finally the column was flushed with 40 ml of 
eluting buffer 3 (20 mM Kphos, 150 mM NaCl, 25 M PLP, 500 mM imidazole, pH 
8.0). 
 Fractions from the 3 eluting buffers and the binding buffer were collected but 
only fractions from eluting buffer 2 and 3 were dialysed overnight (using BioDesign 
Dialysis Tubing, 8k MWCO) against  20 mM of dialysis buffer (20 mM KPhos, 150 
mM NaCl, 25 M PLP, 0.1 mM EDTA, pH 7.5). 
 
6.2.4.4 Size Exclusion Chromatography (SEC) 
Protein fractions eluted from buffer 2 and 3 were concentrated to 4ml by centrifuging 
at 3 krpm for 20 minutes (Denley BR401 centrifuge) in a 10000 MWCO filter tube 
(Vivascience, vivaspin). The Sephacryl S200 Hiprep 26/60 column (GE healthcare) 
was used to obtain a higher level of purification of ArnB. The column was 
equilibrated with 1 L 20 mM Phosphate buffer (20 mM KPhos, 150 mM NaCl, 25 M 
PLP, 0.1 mM EDTA, pH 7.5) and the 5ml protein sample was then injected via a 
superloop. The column was run at a 1 ml/min flow rate with an isocratic gradient 
using the same buffer for equilibration and 10 ml fractions were collected.  
 
6.2.4.5 Sephacryl S-200 Column Calibration 
A calibration was performed with low and high molecular weight calibration kits (GE 
Healthcare) according to the manufacturer’s guide lines. The column was pre-
equilibrated with 20 mM Tris buffer containing 150 mM NaCl, pH 7.5 and then run 
with Blue Dextran 2000 (1 mg/ml). Its elution volume was referred as the void 
volume, V0. Mixture of low and high molecular weight standards (5 mg/ml each) 
were successively run and the elution volumes noted Ve. The gel phase distribution 
coefficient (Kav) of the protein was calculated as (Ve – V0)/(Vt – V0), where Vt is the 
total volume of the column (320 ml). Kav was plotted against log(Mw) of each sample 
injected (Fig. 6.1) and a linear equation was fitted by Sigmaplot software (Systat 
Software Inc., figure 6.1 inset). 
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Figure 6.1 Calibration curve of Sephacryl S200 Hiprep 26/60 column. 
 
6.2.4.6 Small Scale Expression of ArnG 
ArnG expression was performed with, pET28a-ArnG-NHis, pET28a-ArnG-CHis and 
pET29a-ArnG vectors. Dna plasmid was transformed in BL21(DE3)PlysS competent 
cells. A single colony was added to 20 ml LB media supplemented with kanamycin 
(30 µg/ ml) and grown overnight at 30 °C and 250 rpm. The overnight pre-culture was 
added to 20 ml LB broth with a starting OD of 0.1. Cells were grown at 30 °C until an 
optical density (OD600) of 0.6-0.7 was achieved and induced with 0.5 mM or 1 mM of 
IPTG for 6 hours. One ml of each sample (induced and non induced) was pelleted and 
re-suspended in 1 ml of SDS buffer (1.5 M Tris, 2 ml 100% (v/v) glycerol, 2 ml 
0.05% (w/v) bromophenol Blue, pH 8.0) and agitated overnight at 4 °C. Cell extracts 
containing ArnG were run on gel and detected by western blot (see 6.2.4.8). 
  
6.2.4.7 Purification of ArnG 
ArnG expressing pellet was re-suspended in 25 mM HEPES buffer containing 500 
mM NaCl, 0.1 mM EDTA, 20 % glycerol (v/v), 1 % sodium dodecyl sulphate (SDS) 
and 20 mM imidazole, pH 8.0. The re-suspended pellet was stirred at 120 rpm  at 4 oC 
for 2 hours and then centrifuged at 13000 rpm at 4 oC for 1 hour and the supernatant 
kept. 
 Nickel-NTA resin (Qiagen) was prepared as mentioned in section 6.2.4.3. The 
resin was re-suspended in 5 ml of binding buffer (20 mM HEPES, 500 mM NaCl, 20 
mM imidazole, and 0.1 % of SDS, pH 8.0), centrifuged for 5 minutes at 3000 rpm and 
y = -0.551x + 2.8566 
y: Kav 
x: log(Mw) 
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the supernatant removed. Cell extract containing the protein was then incubated with 
the prepared resin for 2 hours at 4 oC in a shaker at 120 rpm. The preparation was then 
loaded onto the column (Qiagen Polypropylene Column) and a peristaltic pump was 
then used to elute the protein. 
 Three eluting buffers were used to isolate the protein; 20 ml of eluting buffer 1 
(25 mM HEPES, 500 mM NaCl, 20 mM imidazole, 0.1% n-Dodecyl--maltoside 
(DDM), pH 8.0) was added to the column. Then 20 ml eluting buffer 2 (25 mM 
HEPES, 500 mM NaCl, 100 mM imidazole, 0.1% DDM, pH 8.0) was added to elute 
the protein. Finally the column was flushed with 40 ml of eluting buffer 3 (25 mM 
HEPES, 500 mM NaCl, 250 mM imidazole, 0.1% DDM, pH 8.0). 
 Western blot technique was used to determine fractions containing ArnG. 
 
6.2.4.8 Western Blot 
After SDS-PAGE, the gel was disposed with a piece of nitrocellulose membrane 
(HybondTM-ECLTM, Amersham) of similar size in a transfer buffer for 10 mins at 
room temperature and under agitation. Six pieces of filter paper (Whatman) of slighty 
longer size than the gel were soaked in the transfer buffer and placed back to back (3 
each) with the gel and the membrane in the Trans-Blot®Semi-Dry Transfer Cell (Bio-
Rad). The membrane was blotted at 15 V and 120 mA for 45 minutes. The membrane 
was then placed in blocking solution (25 ml 1 x PBS, 0.01% (v/v) tween, 5% (w/v) 
dried skimmed milk) overnight at 4 oC under agitation. 
 The membrane was placed in washing solution (PBS, 0.01% tween) and 
washed 3 x 5 mins followed by 3 x 10 mins under agitation. Then, an anti-His 
antibody solution (25 ml PBS, 0.01% (v/v) tween, 5% (w/v) dried skimmed milk, 2.5 
l anti-His antibody (GE Healthcare) was added and left for 1 hour at room 
temperature under agitation. The wash step was repeated and the membrane was then 
placed in an anti-IgG antibody solution (25 ml PBS, 0.01% (v/v) tween, 5% (w/v) 
dried skimmed milk, 2.5 l anti-mouse IgG-Hrp-linked antibody (Cell Signalling 
Technology)). After a last wash step, the membrane was dried and soaked in an ECL 
Plus Western Blotting solution (GE Healthcare) for 2 minutes. The membrane was 
then covered by a cling film before being developed on a KODAK BioMax Xar film 
in a HypercassetteTM (Amersham) for 30 s to 15 minutes. 
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6.2.5 Protein Assays 
 
6.2.5.1 Spectroscopic Measurements  
All UV-visible spectra were recorded on a Varian’s Cary 50 UV-Vis 
spectrophotometer and analysed using Cary WinUV software (Varian). All assays 
were carried out at 30 °C. All chemicals were purchased from Sigma-Aldrich with the 
exception of ibotenic acid (Ascent scientific). 
 Before every spectroscopic experiment, the enzyme was reconstituted with 
PLP by dialysing it  overnight at 4 °C against 20 mM potassium phosphate (pH 7.5) 
containing 150 mM NaCl and 25 M PLP. Unbound PLP was then discarded by 
passing the reconstituted protein through a PD-10 desalting column (Sephadex G-
25M, GE Healthcare). The final concentration of recombinant ArnB-PLP was 10 M. 
Typically assays contained 10 M ArnB (Calculated with the BCA assay – see 
section 6.1.4.1) in 20 mM potassium phosphate (pH 7.5) and were carried out in a 500 
µL quartz cuvette (1 cm path length). 
 
6.2.5.2 ArnB Aminotransfer and Inhibition Assays 
Varying amounts of amino acids were used to assay the protein (0-1 mM). With the 
exception of L-glutamate (0-100 M), all the amino acids tested were added in large 
excess (1 mM) compared to ArnB-PLP.  After addition of the substrate, the reactants 
were mixed and the reaction monitored immediately. For L-glutamate spectra, small 
baseline changes were corrected using Sigma Plot software. For L-methionine and L-
cysteine assays, the ratio A420/A330 was calculated and plotted against time. Resulting 





The Yobs is the observed ratio A420/A330, Y0 is the ratio A420/A330 at time zero and Y- 
is the ratio A420/A330 at the end of the reaction. K is the pseudo first order rate of the 
reaction and t is the time. 
 
 
Yobs = ((Y0 - Y-)e
-kt) + Y-    (1)  
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6.2.6 Antibacterial Assays 
 
6.2.6.1 Disk Diffusion Tests 
Single colonies of B. cenocepacia strain J2315, - SAL-1, -  B. multivorans ATCC 
17616, - LMG 13010, P. aeruginosa PAO1,  E. coli K12 MG1655, and S. aureus 
were picked and grown in 5 ml IS broth at 37°C overnight. The A600 was measured 
and the cultures were diluted in IS broth to an A600 of ~ 0.2. Two ml of diluted liquid 
culture of each strain was equally spread onto ISA plates containing different 
concentrations of polymyxin B (0-, 0.06-, 0.12-, 0.25-, 0.5-, 1-, 2-, 4-, 8-, 16-, 32-, 64-
, 125-, 250-, 500-, 1000- g). After ~30 s, the remaining fluid was suctioned, and the 
plates were dried for 1 hour.  
 D-cycloserine was dissolved in dH2O, and sterile Whatman filter paper disks 
were dotted with 250 g, 50 g, and 10 g by adding 4 l of stock solutions of 
different concentrations. The filter disks were then directly placed on top of the agar 
plates. The plates were incubated for 24 hours at 37°C.  
 
6.2.6.2 Minimal Inhibitory Concentration (MIC) 
MIC data was generated as in the JAC guidelines [1]. Single colonies of the strains 
listed in table 5.1 (Section 5.5) were picked and grown overnight in 10 ml nutrient 
broth + 0.5% yeast extract. The next day, the overnights were diluted 1/10 in fresh 
broth and grown for an additional 2 h. at 37 ºC (mid-log phase). All strains were 
diluted 10 times in Saline (NaCl). This dilution was used as inoculum for the 
multipoint inoculator.  This gives the recommended inoculum of 104 cfu/spot.   
The plates, containing different concentrations of antibiotic ranging from 0 to 500 
g/ml (0, 1, 2, 4, 6, 8, 10, 12.5, 15, 20, 30, 40, 50, 75, 100, 125, 175, 200, 250, 300, 
400, 500), were inoculated, allowed to dry, and incubated at 37 oC for 18 hours. 
 MICs values were taken according to the concentration of antibiotic where no 
growth could be observed. 
 
6.2.7 Complementation Assays of ArnG in E. coli Knock-out Strains 
E. coli knock-out strains AY100, AY101 and AY102 were made either chemically 
competent or electrocompetent. Cells were electroporated or transformated with the 
pTrc99a-ArnG vector. Systematically, the pTrc99a/FbpA plasmid (P. Bilton, PhD, 
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Ferric binding protein A) was also used as a control for the complementation tests. 
After transformation, cells were grown on plate with the appropriate antibiotic 
(kanamycin and/or ampicillin). One single colony was used to inoculate 10 ml of LB 
broth overnight at 30 ºC. This growth was then subcultured in 10 ml LB and further 
grown for 6 hours. The different cultures were then normalised at A600 and diluted as 
follows; 10-1, 10-2, 10-3 and 10-4. Cells were spotted (3 l) on PMB plate (0-15 g/ml) 




1 Andrews, J. M. (2001) J. Antimicrob. Chemother. 48 Suppl, 5-16 
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